Medicine – Renal Transplantation

Renal transplantation, or kidney transplantation, is an established treatment for end-stage kidney disease (ESKD). A functioning donor kidney is transplanted into the recipient, restoring renal filtration and many of the endocrine and metabolic functions of the kidneys.

For suitable patients, kidney transplantation generally provides better long-term survival and quality of life than remaining on dialysis, although recipients require lifelong monitoring and usually long-term immunosuppression.

1. Indication for Renal Transplantation

The principal indication is:

End-stage kidney disease.

Patients may reach ESKD because of conditions such as:

Diabetic kidney disease.

Glomerulonephritis.

Polycystic kidney disease.

Hypertensive kidney disease.

Congenital or hereditary renal disorders.

2. Timing of Transplantation

Transplantation can occur after a patient has started:

Haemodialysis

or

Peritoneal dialysis.

However, when possible, transplantation may be performed before long-term dialysis becomes necessary.

This is called:

Pre-emptive kidney transplantation.

3. UK Transplant Numbers

The original note states:

“In the UK, 2000 patients per year.”

This is an old historical figure and should not be memorised as a current fixed number.

The number of kidney transplants performed each year changes according to:

Organ availability.

Living donation.

Deceased donation.

Waiting-list activity.

Transplantation policy.

For examinations, the principles of transplantation are usually more important than an old annual transplant number.

4. Sources of Donor Kidneys

Kidneys may come from:

Living donors

or

Deceased donors.

Both are important sources of transplantable kidneys.

5. Living Donors

Living donors may include:

Biologically related donors.

Spouses or partners.

Friends or other suitable individuals.

Living donation has become considerably more important than the historical figure of:

10–15% of transplants

suggests.

Therefore, that percentage should be regarded as outdated rather than a current universal figure.

6. Advantages of Living-Donor Transplantation

Living-donor transplantation has several potential advantages.

These include:

Planned timing of surgery.

Shorter cold-ischaemia time.

Possibility of pre-emptive transplantation.

Generally excellent graft outcomes.

The donor must undergo careful medical and psychological assessment to ensure that donation is acceptably safe.

7. Deceased Donors

Deceased-donor kidneys may be obtained after:

Donation after brain death

or

Donation after circulatory death.

Allocation depends on multiple factors, including compatibility and national allocation policies.

8. Graft Survival

The original figures state:

90% graft survival at 1 year

and

70% at 5 years.

These are historical figures and should not be treated as current universal survival rates.

Modern graft survival varies according to:

Living versus deceased donation.

Recipient characteristics.

Donor characteristics.

Immunological risk.

Definition of graft survival used.

Transplant era and centre.

In general, modern outcomes are better than many older textbook figures suggest.

9. Pre-Transplant Assessment

Before transplantation, both recipient and donor require careful assessment.

The recipient is evaluated for:

Cardiovascular disease.

Active infection.

Malignancy.

Immunological compatibility.

Ability to tolerate surgery and immunosuppression.

Other major comorbidities.

10. ABO Blood-Group Compatibility

Traditionally, the donor and recipient should be:

ABO compatible.

This reduces the risk of antibodies in the recipient attacking blood-group antigens expressed by the graft.

11. Rhesus Factor

The original note correctly states:

Rhesus matching is not important in kidney transplantation.

Unlike red-cell transfusion:

Rh compatibility is not a major requirement for renal transplantation.

Therefore:

ABO matters; Rh generally does not.

12. ABO-Incompatible Transplantation

An important modern development is that:

ABO incompatibility is no longer an absolute barrier in selected patients.

Specialist programmes may use:

Antibody removal

and

Immunosuppressive strategies

to permit selected ABO-incompatible living-donor transplants.

However, ABO-compatible transplantation remains simpler and preferable when available.

13. HLA System

Another important part of transplantation immunology is:

Human leukocyte antigen – HLA – matching.

HLA molecules are important components of the immune system and help distinguish:

Self from non-self.

Differences between donor and recipient HLA can trigger immune recognition of the transplanted kidney.

14. HLA Genes

The major HLA genes are located on:

Chromosome 6.

More specifically, they are located within the:

Major histocompatibility complex – MHC.

15. Important HLA Types

Historically, kidney transplantation focused heavily on matching:

HLA-A.

HLA-B.

HLA-DR.

HLA-C and other loci can also have immunological relevance.

16. Historical Importance of HLA Matching

Older teaching often ranked matching approximately as:

DR > B > A > C.

HLA-DR matching was considered particularly important.

However, modern transplantation uses a much more sophisticated assessment of immunological compatibility than simply counting these mismatches.

17. Modern HLA Assessment

Modern assessment may consider:

HLA mismatches.

Pre-existing anti-HLA antibodies.

Donor-specific antibodies – DSA.

Calculated sensitisation levels.

Crossmatch results.

Therefore, a simple rule such as:

“One DR or one B mismatch is acceptable”

is too rigid for modern transplantation.

18. Sensitisation

Some recipients have previously developed antibodies against HLA antigens.

This is called:

Sensitisation.

Sensitisation may occur following:

Previous transplantation.

Pregnancy.

Blood transfusion.

Highly sensitised patients may have greater difficulty finding a compatible donor.

19. Donor-Specific Antibodies

Particular attention is given to:

Donor-specific antibodies – DSA.

These are recipient antibodies directed against HLA antigens present on the proposed donor kidney.

They increase the risk of:

Antibody-mediated rejection.

20. Crossmatching

Before transplantation, a:

Crossmatch

is performed to determine whether the recipient has antibodies capable of reacting against the donor.

A strongly positive crossmatch generally indicates a high risk of:

Hyperacute or severe antibody-mediated rejection.

21. Why Matching Matters

The purpose of compatibility testing is to reduce the risk of:

Rejection.

Early graft loss.

Chronic graft injury.

However, transplantation decisions balance immunological matching against other factors such as:

Waiting time.

Donor quality.

Recipient urgency.

22. Kidney Transplant Operation

The donor kidney is usually placed:

Extraperitoneally in the iliac fossa.

The donor renal artery and vein are connected to the recipient’s:

Iliac vessels.

The donor ureter is implanted into the:

Bladder.

23. What Happens to the Patient’s Own Kidneys?

The patient’s native kidneys are usually:

Left in place.

They are removed only when there is a particular indication, such as selected cases involving:

Recurrent infection.

Malignancy.

Severe symptoms from very large polycystic kidneys.

24. Need for Immunosuppression

The transplanted kidney contains donor antigens that can be recognised as foreign by the recipient’s immune system.

Without adequate immunosuppression, this can cause:

Graft rejection.

Therefore, most recipients require long-term:

Immunosuppressive therapy.

25. Induction and Maintenance Immunosuppression

Modern immunosuppression can broadly be divided into:

Induction therapy

and

Maintenance therapy.

Induction therapy provides strong immunosuppression around the time of transplantation.

Maintenance therapy is continued long-term.

26. Maintenance Immunosuppression

The original notes describe:

Triple therapy.

This remains an important general concept.

A common maintenance regimen includes:

A calcineurin inhibitor.

An antiproliferative agent.

Corticosteroid therapy in many protocols.

Exact regimens vary according to recipient risk and transplant centre.

27. Calcineurin Inhibitors

The main calcineurin inhibitors are:

Tacrolimus

and

Ciclosporin.

In modern practice:

Tacrolimus is commonly preferred.

28. Tacrolimus

Tacrolimus suppresses:

T-cell activation

by inhibiting:

Calcineurin.

It is highly effective at reducing acute rejection.

Important adverse effects include:

Nephrotoxicity.

Hypertension.

Hyperkalaemia.

Neurotoxicity.

Diabetes mellitus.

29. Ciclosporin

Ciclosporin is another:

Calcineurin inhibitor.

Adverse effects include:

Nephrotoxicity.

Hypertension.

Hyperlipidaemia.

Gingival hyperplasia.

Hirsutism.

30. Antiproliferative Drugs

The second major maintenance component is commonly an antiproliferative agent.

Examples include:

Mycophenolate mofetil / mycophenolic acid

or

Azathioprine.

Mycophenolate is commonly used in modern transplant regimens.

31. Mycophenolate

Mycophenolate inhibits lymphocyte proliferation.

Important adverse effects include:

Diarrhoea and other gastrointestinal symptoms.

Bone-marrow suppression.

Leukopenia.

It is also:

Teratogenic.

32. Azathioprine

Azathioprine suppresses:

Purine synthesis and lymphocyte proliferation.

Important adverse effects include:

Bone-marrow suppression.

Hepatotoxicity.

Long-term immunosuppression involving azathioprine has also been associated with increased:

Skin-cancer risk.

33. Corticosteroids

Prednisolone may form the third component of maintenance therapy.

Long-term corticosteroid adverse effects include:

Diabetes.

Hypertension.

Osteoporosis.

Weight gain.

Infection.

Cushingoid features.

Some modern protocols minimise or withdraw steroids in selected recipients.

34. Induction Therapy

At transplantation, selected patients receive powerful induction immunosuppression.

Agents may include:

Basiliximab

or

T-cell-depleting therapies such as antithymocyte globulin.

The choice depends on the recipient’s immunological risk and local protocol.

35. Major Post-Transplant Complications

Important complications include:

Rejection.

Infection.

Malignancy.

Cardiovascular disease.

Hypertension.

Metabolic complications.

Drug toxicity.

Recurrence of the original kidney disease.

36. Hyperacute Rejection

Hyperacute rejection occurs within:

Minutes to hours

after transplantation.

It results from pre-existing recipient antibodies against donor antigens.

These antibodies cause:

Complement activation.

Endothelial injury.

Thrombosis.

Rapid graft failure.

37. Prevention of Hyperacute Rejection

Modern:

Crossmatching

and

Antibody screening

have made hyperacute rejection much less common.

A severely affected graft may be irreversibly damaged.

38. Acute Rejection

Acute rejection can occur from:

T-cell-mediated rejection

or

Antibody-mediated rejection.

It may occur early after transplantation but can also occur later, particularly when immunosuppression is inadequate.

39. Presentation of Acute Rejection

Possible features include:

Rising serum creatinine.

Reduced graft function.

Reduced urine output.

Sometimes:

Graft tenderness.

Fever.

However, modern rejection may be detected primarily through:

Laboratory abnormalities.

40. Diagnosis of Rejection

Evaluation may include:

Serum creatinine.

Urinalysis.

Drug levels.

Ultrasound.

Donor-specific antibody testing.

A:

Transplant kidney biopsy

is often required to determine the exact type of rejection.

41. Chronic Graft Dysfunction

Long-term graft dysfunction can result from multiple processes rather than a single entity called simply “chronic rejection.”

Causes include:

Chronic antibody-mediated rejection.

Calcineurin-inhibitor toxicity.

Recurrent disease.

Hypertension.

Infection.

Other chronic graft injuries.

42. Infection after Transplantation

Immunosuppression increases susceptibility to:

Bacterial infections.

Viral infections.

Fungal infections.

Opportunistic infections.

The type of infection depends partly on:

Time since transplantation

and

Intensity of immunosuppression.

43. Pneumocystis Pneumonia

The original term:

Pneumocystis carinii pneumonia

is outdated in humans.

The organism causing human disease is:

Pneumocystis jirovecii.

Therefore the preferred term is:

Pneumocystis jirovecii pneumonia – PJP.

The abbreviation PCP is still sometimes encountered historically.

44. Prevention of Pneumocystis Infection

Transplant recipients commonly receive prophylaxis with:

Trimethoprim-sulfamethoxazole

for a defined period after transplantation, according to local protocol.

This reduces the risk of:

PJP.

It also provides protection against certain other infections.

45. Cytomegalovirus

Cytomegalovirus – CMV is one of the most important viral infections after transplantation.

Risk depends strongly on the:

CMV status of donor and recipient.

A particularly high-risk combination is:

CMV-positive donor → CMV-negative recipient.

46. CMV Manifestations

CMV can cause:

Fever.

Bone-marrow suppression.

Gastrointestinal disease.

Pneumonitis.

Hepatitis.

Retinitis.

Other organ involvement may occur.

47. CMV Prevention and Treatment

High-risk patients may receive antiviral prophylaxis such as:

Valganciclovir

according to transplant protocol.

Established disease is treated with appropriate:

Anti-CMV antiviral therapy.

48. BK Polyomavirus

An important modern transplant infection not mentioned in the original notes is:

BK polyomavirus.

Reactivation under immunosuppression can cause:

BK virus nephropathy.

This can progressively damage the transplanted kidney.

49. BK Virus Management

Patients may undergo monitoring for:

BK viraemia.

When significant BK infection occurs, management often requires carefully:

Reducing immunosuppression

while balancing the increased risk of rejection.

50. Malignancy after Transplantation

Long-term immunosuppression increases the risk of:

Malignancy.

This occurs because immune surveillance against malignant cells is reduced and oncogenic viral infections become more important.

51. Skin Cancer

Transplant recipients have a markedly increased risk of:

Non-melanoma skin cancer.

In particular:

Cutaneous squamous cell carcinoma

is an important long-term complication.

Sun protection and dermatological surveillance are therefore important.

52. Azathioprine and Skin Cancer

The original note associates:

Azathioprine with skin cancer.

This is a useful association, although the overall cancer risk results from:

Long-term immunosuppression as a whole

rather than one drug alone.

Azathioprine can contribute particularly to:

Photosensitisation and cutaneous carcinogenesis.

53. Post-Transplant Lymphoproliferative Disorder

The original notes list:

Non-Hodgkin lymphoma.

A more specific transplant concept is:

Post-transplant lymphoproliferative disorder – PTLD.

PTLD ranges from abnormal lymphoid proliferation to aggressive lymphoma.

54. EBV and PTLD

PTLD is often associated with:

Epstein–Barr virus – EBV.

The risk is increased by the:

Overall intensity of immunosuppression.

Therefore, it is too simplistic to attribute post-transplant lymphoma specifically to:

Ciclosporin alone.

55. Cardiovascular Disease

Cardiovascular disease remains a major cause of morbidity and mortality after kidney transplantation.

Important risk factors include:

Pre-existing CKD-related cardiovascular disease.

Hypertension.

Diabetes.

Dyslipidaemia.

Smoking.

Effects of immunosuppressive medications.

56. Ischaemic Heart Disease

The original note states:

“IHD is 10–20 times more prevalent.”

This is another historical figure that should not be treated as a fixed modern estimate.

The key point is:

Kidney-transplant recipients remain at substantially increased cardiovascular risk compared with the general population.

57. Hypertension

Hypertension is common after renal transplantation.

Possible causes include:

Pre-existing hypertension.

Calcineurin inhibitors.

Corticosteroids.

Transplant renal artery stenosis.

Chronic graft dysfunction.

Native kidney disease.

58. Post-Transplant Diabetes

Another important metabolic complication is:

Post-transplant diabetes mellitus.

Risk is increased by:

Tacrolimus.

Corticosteroids.

Pre-existing metabolic risk factors.

59. Transplant Renal Artery Stenosis

Renal artery stenosis affecting the transplanted kidney can cause:

Difficult-to-control hypertension

and

Graft dysfunction.

It should therefore be considered in a recipient who develops new or resistant hypertension.

60. Recurrence of Original Renal Disease

The original notes correctly emphasise that the disease responsible for ESKD may:

Recur in the transplanted kidney.

However, recurrence risk differs greatly between diseases.

61. Recurrent Glomerular Disease

Diseases that can recur include:

FSGS.

IgA nephropathy.

Membranous nephropathy.

MPGN / C3 glomerulopathy.

Other glomerular disorders may also recur.

62. FSGS Recurrence

Primary FSGS is particularly important because it can recur:

Very rapidly after transplantation.

The patient may develop:

Heavy proteinuria

soon after transplantation.

63. IgA Nephropathy Recurrence

IgA nephropathy can recur in the transplanted kidney.

Recurrence may be:

Histological only

or may eventually cause:

Proteinuria, haematuria, and graft dysfunction.

64. Anti-GBM Disease and Transplantation

Patients with anti-GBM disease can undergo transplantation once the disease is appropriately controlled.

Transplantation is generally delayed until:

Anti-GBM antibodies have remained undetectable for an appropriate period.

This reduces the risk of recurrence.

65. Surgical and Urological Complications

Renal transplantation can also cause surgical complications such as:

Bleeding.

Renal artery or vein thrombosis.

Urinary leakage.

Ureteric obstruction or stenosis.

Lymphocele formation.

66. Delayed Graft Function

Some transplanted kidneys do not function immediately.

This is called:

Delayed graft function.

It commonly reflects:

Acute tubular injury associated with ischaemia-reperfusion.

Temporary dialysis may be required while the graft recovers.

67. Monitoring after Transplantation

Long-term follow-up includes monitoring of:

Serum creatinine and eGFR.

Proteinuria.

Blood pressure.

Electrolytes.

Immunosuppressant drug levels.

Blood glucose and lipids.

Infection.

Malignancy.

Cardiovascular risk.

68. Renal Transplantation – Matching Note Form

ABO:

Usually compatible.

Selected ABO-incompatible transplantation is possible with specialist protocols.

Rhesus:

Not clinically important for kidney matching.

HLA:

Genes located on chromosome 6.

HLA-A, HLA-B and HLA-DR have historically been major matching loci.

Modern matching also considers broader HLA characteristics.

Donor-specific antibodies:

Increase risk of antibody-mediated rejection.

Crossmatch:

Determines whether recipient antibodies react against the donor.

A significant positive crossmatch indicates high immunological risk.

69. Renal Transplantation – Immunosuppression Note Form

Calcineurin inhibitor:

Tacrolimus commonly used.

Ciclosporin alternative.

Antiproliferative drug:

Mycophenolate commonly used.

Azathioprine alternative.

Corticosteroid:

Prednisolone used in many regimens.

Some protocols minimise steroids.

Typical concept:

Calcineurin inhibitor + antiproliferative agent ± corticosteroid.

70. Renal Transplantation – Rejection Note Form

Hyperacute rejection:

Minutes to hours.

Pre-existing antibodies.

Thrombosis and rapid graft failure.

Acute rejection:

T-cell-mediated or antibody-mediated.

Often presents with rising creatinine.

Biopsy commonly required.

Chronic graft dysfunction:

Multifactorial.

May involve chronic antibody-mediated injury, drug toxicity, recurrent disease and other causes.

71. Renal Transplantation – Infection Note Form

Pneumocystis jirovecii:

Opportunistic pneumonia.

Prophylaxis commonly used.

CMV:

Important opportunistic viral infection.

May cause systemic and organ-specific disease.

BK polyomavirus:

Can cause transplant nephropathy and graft dysfunction.

Other infections:

Bacterial, fungal and viral infections occur because of immunosuppression.

72. Renal Transplantation – Malignancy Note Form

Skin cancer:

Particularly cutaneous squamous cell carcinoma.

Strongly increased by chronic immunosuppression.

PTLD:

Post-transplant lymphoproliferative disorder.

Often associated with EBV.

Can include non-Hodgkin-type lymphomas.

73. Important Corrections to the Original Notes

The UK figure:

“2000 renal transplants per year”

is historical and should not be memorised as a current number.

The graft-survival figures:

“90% at 1 year and 70% at 5 years”

are also historical.

Modern outcomes vary by donor and recipient factors and are generally better than many older textbook figures.

The statement:

“Live donors = 10–15%”

is outdated as a universal figure.

Living donation now contributes substantially to transplantation programmes.

The old HLA rules:

“DR > B > A > C”

and

“one DR or B mismatch acceptable”

are useful historical simplifications but do not represent the full modern approach.

Modern assessment includes:

HLA compatibility + donor-specific antibodies + sensitisation + crossmatching.

The term:

Pneumocystis carinii pneumonia

should be replaced with:

Pneumocystis jirovecii pneumonia – PJP.

The association:

“Non-Hodgkin lymphoma especially with ciclosporin”

is better understood as:

PTLD, often EBV-related, associated with the overall intensity of immunosuppression.

The statement:

“All glomerulonephritides can recur”

is too broad.

Many primary renal diseases can recur after transplantation, but:

The probability, timing and clinical significance of recurrence differ substantially between diseases.

Key Clinical Pattern

For matching, remember:

ABO COMPATIBILITY + HLA ASSESSMENT + DONOR-SPECIFIC ANTIBODIES + CROSSMATCH.

For maintenance immunosuppression, think:

TACROLIMUS + MYCOPHENOLATE ± PREDNISOLONE.

For major complications, remember:

REJECTION + INFECTION + MALIGNANCY + CARDIOVASCULAR DISEASE + DRUG TOXICITY + RECURRENT RENAL DISEASE.

High-yield transplant associations:

TACROLIMUS → NEPHROTOXICITY + DIABETES.

CICLOSPORIN → NEPHROTOXICITY + HYPERTENSION + GINGIVAL HYPERPLASIA + HIRSUTISM.

AZATHIOPRINE → BONE-MARROW SUPPRESSION + SKIN-CANCER RISK.

PJP → OPPORTUNISTIC PNEUMONIA.

CMV → IMPORTANT POST-TRANSPLANT VIRAL INFECTION.

BK VIRUS → TRANSPLANT NEPHROPATHY.

EBV → PTLD.

And the central principle is:

A SUCCESSFUL KIDNEY TRANSPLANT REQUIRES A BALANCE BETWEEN ENOUGH IMMUNOSUPPRESSION TO PREVENT REJECTION AND NOT SO MUCH THAT INFECTION, MALIGNANCY AND DRUG TOXICITY BECOME EXCESSIVE.

Medicine – Renal Syndromes

Renal disorders commonly present in a limited number of recognisable clinical syndromes. Identifying the syndrome first helps narrow the differential diagnosis before determining the exact underlying disease.

The main renal syndromes include:

Asymptomatic proteinuria.

Nephrotic syndrome.

Nephritic syndrome.

Haematuria.

Acute kidney injury.

Chronic kidney disease.

1. Asymptomatic Proteinuria

Asymptomatic proteinuria means protein is detected in the urine without obvious oedema, haematuria, renal failure, or other major symptoms.

Older teaching sometimes defines this as:

Proteinuria less than 3 g/day.

However, modern practice more often classifies proteinuria by:

Urine albumin-to-creatinine ratio – ACR

or

Protein-to-creatinine ratio – PCR.

2. Why Proteinuria Matters

Persistent proteinuria may be an early sign of:

Glomerular disease.

Diabetic kidney disease.

Hypertensive kidney disease.

Tubulointerstitial disease.

It may also occur transiently during:

Fever.

Exercise.

Acute illness.

Therefore, persistent proteinuria should usually be confirmed with repeat testing.

3. Nephrotic Syndrome

Nephrotic syndrome results from marked increase in glomerular permeability to plasma proteins.

The classic features are:

Heavy proteinuria.

Hypoalbuminaemia.

Oedema.

Hyperlipidaemia.

4. Proteinuria in Nephrotic Syndrome

Older notes often use:

Proteinuria greater than 3 g/day.

The more commonly used adult threshold is approximately:

Greater than 3–3.5 g/day.

In practice, nephrotic-range proteinuria may also be estimated using a:

Urine protein-to-creatinine ratio.

5. Hypoalbuminaemia

Because large amounts of albumin are lost in the urine, serum albumin falls.

A classic nephrotic value is:

Serum albumin below about 25–30 g/L.

The exact threshold varies, but marked hypoalbuminaemia supports the diagnosis.

6. Oedema in Nephrotic Syndrome

Loss of albumin lowers plasma oncotic pressure.

This promotes movement of fluid from the circulation into the tissues, producing:

Peripheral oedema.

Periorbital oedema.

Ascites.

Generalised oedema in severe cases.

7. Hyperlipidaemia

The liver responds to low oncotic pressure by increasing synthesis of:

Lipoproteins.

Therefore nephrotic syndrome is commonly associated with:

Hypercholesterolaemia.

Hypertriglyceridaemia.

8. Lipiduria

Lipid may also appear in the urine.

Urine microscopy can demonstrate:

Oval fat bodies.

These may show a:

Maltese-cross appearance

under polarised light.

9. Causes of Nephrotic Syndrome

Important causes include:

Minimal change disease.

FSGS.

Membranous nephropathy.

Diabetic kidney disease.

Amyloidosis.

SLE.

Infections.

Drugs.

10. Complications of Nephrotic Syndrome

Nephrotic syndrome can lead to important complications.

These include:

Venous thromboembolism.

Infection.

Malnutrition.

Vitamin D loss.

Hypocalcaemia.

Hyperlipidaemia.

11. Why Thrombosis Occurs

Patients lose anticoagulant proteins in the urine, including:

Antithrombin.

At the same time, some procoagulant factors increase.

This creates a:

Hypercoagulable state.

12. Nephritic Syndrome

Nephritic syndrome results from inflammatory injury to the glomeruli.

The classic features include:

Haematuria.

Hypertension.

Oedema.

Oliguria.

Reduced GFR.

Proteinuria, usually less severe than in nephrotic syndrome.

13. Haematuria in Nephritic Syndrome

Haematuria may be:

Microscopic

or

Macroscopic.

Urine may appear:

Tea-coloured

or

Cola-coloured.

This suggests glomerular bleeding.

14. Dysmorphic Red Cells

Glomerular haematuria often produces:

Dysmorphic red blood cells.

These become distorted while passing through a damaged glomerular filtration barrier.

15. Red Blood Cell Casts

A particularly important finding is:

Red blood cell casts.

These strongly suggest:

Glomerulonephritis.

Therefore:

Haematuria + RBC casts + reduced GFR → think nephritic glomerular disease.

16. Hypertension in Nephritic Syndrome

Hypertension develops because impaired filtration leads to:

Sodium retention.

Water retention.

Increased intravascular volume.

This can also contribute to:

Oedema.

17. Oliguria

Oliguria means:

Reduced urine output.

It occurs because inflamed glomeruli filter less plasma.

Severe cases may progress to:

Acute kidney injury.

18. Proteinuria in Nephritic Syndrome

Proteinuria is usually:

Mild to moderate.

However, some diseases can produce a mixed:

Nephritic-nephrotic pattern.

Therefore, heavy proteinuria does not completely exclude inflammatory glomerulonephritis.

19. Causes of Nephritic Syndrome

Important causes include:

Post-infectious glomerulonephritis.

IgA nephropathy.

Lupus nephritis.

ANCA-associated vasculitis.

Anti-GBM disease.

Membranoproliferative GN.

20. Nephrotic versus Nephritic – Note Form

Nephrotic syndrome:

Heavy proteinuria.

Hypoalbuminaemia.

Generalised oedema.

Hyperlipidaemia.

Lipiduria.

Thrombosis risk.

Nephritic syndrome:

Haematuria.

RBC casts.

Hypertension.

Oedema.

Oliguria.

Reduced GFR.

Usually less proteinuria than nephrotic syndrome.

21. Haematuria as a Renal Syndrome

Haematuria means blood in the urine.

It can be:

Microscopic

or

Macroscopic.

22. Microscopic Haematuria

Microscopic haematuria means red blood cells are detected on:

Urine microscopy

or inferred from:

Positive urine dipstick for blood

with confirmation where appropriate.

The urine may look completely normal.

23. Macroscopic Haematuria

Macroscopic haematuria means:

Visible blood in the urine.

The urine may appear:

Pink.

Red.

Brown.

Tea-coloured.

The colour and associated features may help localise the source.

24. Glomerular Haematuria

Features suggesting a glomerular source include:

Dysmorphic RBCs.

RBC casts.

Proteinuria.

Tea- or cola-coloured urine.

Associated renal impairment.

25. Non-Glomerular Haematuria

Features suggesting bleeding from elsewhere in the urinary tract include:

Clots.

Bright red urine.

Relatively normal-shaped RBCs.

Possible causes include:

Stones.

UTI.

Tumours.

Trauma.

26. Glomerulonephritis

Glomerulonephritis is an inflammatory or immune-mediated condition affecting the:

Renal glomeruli.

It can cause:

Haematuria.

Proteinuria.

Reduced GFR.

Hypertension.

Nephritic syndrome.

Nephrotic syndrome in some conditions.

27. Structural Changes in Glomerulonephritis

Possible pathological changes include:

Cellular proliferation.

Leukocyte infiltration.

Immune deposition.

Basement membrane abnormalities.

Crescent formation.

Glomerular sclerosis.

28. Interstitial Nephritis

Interstitial nephritis is an inflammatory disorder involving primarily the:

Renal interstitium

and

Tubules.

This is distinct from glomerulonephritis, which primarily affects:

Glomeruli.

29. Acute Interstitial Nephritis

The acute form commonly presents with:

Acute kidney injury.

Sterile pyuria.

Mild proteinuria.

Microscopic haematuria.

White blood cell casts.

30. Common Causes of Interstitial Nephritis

Important causes include:

Drugs.

Infections.

Autoimmune disease.

Drug-induced disease is especially common.

31. High-Yield Anatomical Distinction

Remember:

Glomerulonephritis → glomeruli.

Interstitial nephritis → interstitium and tubules.

Pyelonephritis → renal interstitium and collecting system, usually due to infection.

32. Acute Kidney Injury as a Renal Syndrome

Although not included in the original list, another major renal syndrome is:

Acute kidney injury – AKI.

AKI is defined by an acute deterioration in renal function, usually detected by:

Rising serum creatinine

and/or

Reduced urine output.

33. Causes of AKI

AKI is commonly divided into:

Pre-renal causes.

Intrinsic renal causes.

Post-renal causes.

34. Pre-Renal AKI

Pre-renal AKI occurs because of reduced renal perfusion.

Examples include:

Hypovolaemia.

Haemorrhage.

Sepsis.

Heart failure.

35. Intrinsic Renal AKI

Intrinsic renal causes include:

Acute tubular injury.

Glomerulonephritis.

Acute interstitial nephritis.

Renal vascular disease.

36. Post-Renal AKI

Post-renal AKI results from:

Urinary tract obstruction.

Examples include:

Prostatic obstruction.

Stones.

Tumours.

Bilateral ureteric obstruction.

37. Chronic Kidney Disease as a Renal Syndrome

Another major presentation is:

Chronic kidney disease – CKD.

CKD refers to persistent abnormalities of kidney structure or function lasting:

At least 3 months.

38. CKD Features

Patients may have:

Reduced eGFR.

Persistent albuminuria.

Hypertension.

Anaemia.

Electrolyte abnormalities.

Mineral and bone disease.

Uraemic symptoms in advanced disease.

39. Renal Syndromes – Note Form

Asymptomatic proteinuria:

Protein detected without major symptoms.

May be early glomerular or systemic renal disease.

Confirm persistence.

Nephrotic syndrome:

Heavy proteinuria.

Hypoalbuminaemia.

Oedema.

Hyperlipidaemia.

Lipiduria.

Nephritic syndrome:

Haematuria.

RBC casts.

Hypertension.

Oedema.

Oliguria.

Reduced GFR.

Haematuria syndrome:

Microscopic or visible haematuria.

Determine whether glomerular or non-glomerular.

AKI:

Rapid deterioration in renal function.

Pre-renal, intrinsic, or post-renal.

CKD:

Persistent kidney abnormality for at least 3 months.

May involve reduced eGFR and/or albuminuria.

40. Important Corrections to the Original Notes

The statement:

“Asymptomatic proteinuria <3 g/day”

is an older simplified definition.

Modern assessment generally uses:

ACR or PCR

and focuses on whether proteinuria is:

Persistent

and whether it reaches:

Nephrotic range.

The statement:

“Nephrotic syndrome = proteinuria >3 g/day”

is broadly correct but modern adult teaching more often uses approximately:

>3–3.5 g/day

or an equivalent spot urine protein measurement.

The original nephrotic definition should also explicitly include:

Hyperlipidaemia

and often:

Lipiduria.

The original nephritic definition is incomplete without:

Reduced GFR

and the high-yield urinary finding:

RBC casts.

Glomerulonephritis and interstitial nephritis should be distinguished anatomically:

GN → GLOMERULI.

INTERSTITIAL NEPHRITIS → INTERSTITIUM + TUBULES.

Key Clinical Pattern

For nephrotic syndrome, think:

PROTEIN LOSS.

HEAVY PROTEINURIA + LOW ALBUMIN + OEDEMA + HIGH CHOLESTEROL.

For nephritic syndrome, think:

GLOMERULAR INFLAMMATION.

HAEMATURIA + RBC CASTS + HYPERTENSION + OLIGURIA + REDUCED GFR.

For anatomical localisation:

GLOMERULONEPHRITIS → GLOMERULI.

INTERSTITIAL NEPHRITIS → INTERSTITIUM AND TUBULES.

A useful overall approach is:

FIRST IDENTIFY THE RENAL SYNDROME → THEN IDENTIFY THE UNDERLYING DISEASE.

Medicine – Causes of Nephrotic Syndrome

Nephrotic syndrome is a clinical syndrome caused by marked glomerular protein loss. It is characterised by:

Heavy proteinuria.

Hypoalbuminaemia.

Generalised oedema.

Hyperlipidaemia.

Lipiduria.

The causes can be divided broadly into primary glomerular diseases and secondary systemic causes.

1. Diabetes Mellitus

Diabetes mellitus is one of the most important secondary causes of nephrotic-range proteinuria.

Diabetic kidney disease causes progressive damage to the glomerular filtration barrier through:

Glomerular basement membrane thickening.

Mesangial expansion.

Intraglomerular hypertension.

Glomerulosclerosis.

2. Diabetic Nephropathy

As diabetic kidney disease progresses, patients may develop:

Increasing albuminuria.

Heavy proteinuria.

Nephrotic syndrome.

Progressive CKD.

A classic histological finding is:

Kimmelstiel–Wilson nodular glomerulosclerosis.

3. Glomerular Diseases

A major group of causes is:

Primary glomerular disease.

Important nephrotic glomerular disorders include:

Minimal change disease.

Focal segmental glomerulosclerosis.

Membranous nephropathy.

Membranoproliferative glomerulonephritis in some cases.

4. Minimal Change Disease

Minimal change disease is the:

Most common cause of nephrotic syndrome in children.

It is characterised by:

Podocyte foot-process effacement on electron microscopy.

Light microscopy is usually:

Normal or nearly normal.

5. Focal Segmental Glomerulosclerosis

FSGS causes:

Focal and segmental glomerular scarring.

It commonly presents with:

Proteinuria.

Nephrotic syndrome.

Hypertension.

It has a greater risk of progression to CKD than typical minimal change disease.

6. Membranous Nephropathy

Membranous nephropathy is an important cause of:

Adult nephrotic syndrome.

It is characterised by:

Diffuse thickening of the glomerular capillary wall

with:

Subepithelial immune deposits.

Primary cases are often associated with:

PLA2R antibodies.

7. Myeloma

Multiple myeloma can cause renal disease and proteinuria.

However, the mechanism needs clarification.

Myeloma classically produces excess:

Monoclonal immunoglobulin light chains.

These can cause:

Cast nephropathy.

AL amyloidosis.

Monoclonal immunoglobulin deposition disease.

8. Myeloma and Nephrotic Syndrome

Myeloma itself does not always cause a classic albumin-predominant nephrotic syndrome.

Nephrotic syndrome is particularly likely when myeloma is associated with:

AL amyloidosis

or

Monoclonal immunoglobulin deposition disease.

Therefore:

MYELOMA + NEPHROTIC SYNDROME → THINK AL AMYLOIDOSIS OR MONOCLONAL DEPOSITION DISEASE.

9. Amyloidosis

Amyloidosis is an important cause of heavy proteinuria and nephrotic syndrome.

Amyloid deposits accumulate within the kidney, especially in the:

Glomeruli.

This disrupts the filtration barrier and causes:

Marked protein loss.

10. AL Amyloidosis

AL amyloidosis results from:

Monoclonal immunoglobulin light chains.

It is associated with:

Plasma-cell disorders

including:

Multiple myeloma.

Renal presentation commonly includes:

Nephrotic syndrome.

11. AA Amyloidosis

AA amyloidosis results from chronic elevation of:

Serum amyloid A protein.

It is associated with chronic inflammatory or infectious diseases such as:

Rheumatoid arthritis.

Chronic inflammatory disorders.

Tuberculosis.

Chronic osteomyelitis.

It can also cause:

Nephrotic syndrome and progressive CKD.

12. Systemic Lupus Erythematosus

SLE can cause several patterns of lupus nephritis.

Nephrotic syndrome is particularly associated with:

Class V membranous lupus nephritis.

However, severe proliferative lupus nephritis can also cause heavy proteinuria.

13. Lupus Nephritis

Lupus nephritis may present with:

Proteinuria.

Haematuria.

Nephritic syndrome.

Nephrotic syndrome.

Hypertension.

Reduced renal function.

Therefore, the urinary pattern depends on the histological class.

14. Infections

Several infections can cause nephrotic syndrome through:

Immune-complex glomerular injury

or

Secondary amyloidosis.

The original list includes:

Malaria.

Leprosy.

Hepatitis B.

These are recognised associations, although their importance varies by geography and disease prevalence.

15. Hepatitis B

Hepatitis B virus is a classic infectious cause of nephrotic syndrome.

It is particularly associated with:

Membranous nephropathy.

It can also be associated with:

Membranoproliferative glomerulonephritis.

16. Hepatitis C

An important modern addition is:

Hepatitis C virus.

Hepatitis C is particularly associated with:

Mixed cryoglobulinaemia

and

Membranoproliferative glomerulonephritis.

This often produces a mixed nephritic-nephrotic picture.

17. HIV

Another important infectious association is:

HIV.

HIV is classically associated with:

Focal segmental glomerulosclerosis,

especially the collapsing variant.

This can cause:

Heavy proteinuria and nephrotic syndrome.

18. Malaria

Malaria can be associated with glomerular disease and proteinuria.

Certain forms have historically been linked to:

Immune-complex nephropathy

and nephrotic syndrome.

The clinical importance depends heavily on the regional epidemiology.

19. Leprosy

Leprosy can occasionally cause renal disease through:

Immune-complex glomerulonephritis

or

Secondary amyloidosis.

Therefore it can be associated with:

Proteinuria and nephrotic syndrome.

20. Pre-eclampsia

Pre-eclampsia is a pregnancy-specific hypertensive disorder associated with:

New-onset hypertension after 20 weeks’ gestation

plus maternal organ dysfunction, often including:

Proteinuria.

21. Proteinuria in Pre-eclampsia

Proteinuria may become:

Heavy or even nephrotic-range.

This results from glomerular endothelial injury.

The characteristic renal lesion is:

Glomerular endotheliosis.

22. Pre-eclampsia Is Not Usually a Primary Nephrotic Disease

Pre-eclampsia can produce substantial proteinuria and oedema, but the patient should be considered in the context of:

Pregnancy + hypertension + maternal systemic disease.

Therefore it is a secondary cause of nephrotic-range proteinuria rather than a primary nephrotic glomerulopathy.

23. Accelerated or Severe Hypertension

The original notes include:

Accelerated hypertension.

Severe hypertension can injure the glomeruli and renal microvasculature.

This may produce:

Proteinuria.

Haematuria.

AKI.

24. Hypertension and Nephrotic-Range Proteinuria

Typical chronic hypertensive nephrosclerosis usually causes:

Low-to-moderate proteinuria,

not classic heavy nephrotic-range proteinuria.

Therefore, severe nephrotic syndrome in a hypertensive patient should prompt consideration of:

An additional glomerular disease.

However, severe or malignant hypertension can occasionally produce marked proteinuria.

25. Drugs

Several drugs can produce nephrotic syndrome by causing glomerular injury.

The original list includes:

Gold.

Penicillamine.

Captopril.

NSAIDs.

These are recognised associations.

26. Gold

Gold salts were historically used in:

Rheumatoid arthritis.

They can cause:

Membranous nephropathy

and therefore:

Proteinuria or nephrotic syndrome.

Because gold therapy is now rarely used, this is mainly an historical or examination association.

27. Penicillamine

Penicillamine may cause:

Membranous nephropathy.

This can present with:

Heavy proteinuria

or

Nephrotic syndrome.

28. Captopril

Captopril has historically been associated with:

Membranous nephropathy

and significant proteinuria.

This complication is uncommon with modern ACE inhibitor use.

ACE inhibitors overall are more commonly used to:

Reduce proteinuria

rather than cause it.

29. NSAIDs

NSAIDs are particularly important because they can cause more than one form of renal disease.

They are associated with:

Minimal change disease.

Acute interstitial nephritis.

Sometimes the two occur together.

30. NSAIDs and Nephrotic Syndrome

NSAID-associated minimal change disease can produce:

Nephrotic syndrome.

Interestingly, the usual hypersensitivity features of AIN, such as:

Fever.

Rash.

Eosinophilia

may be absent.

31. Malignancy

An important secondary cause not included in the original list is:

Malignancy.

Certain cancers are associated with specific glomerular disorders.

32. Hodgkin Lymphoma

Hodgkin lymphoma is classically associated with:

Minimal change disease.

The renal disease may improve when the underlying lymphoma is treated.

33. Solid Tumours

Some solid malignancies are associated with:

Membranous nephropathy.

The relationship is particularly important in older adults with otherwise unexplained membranous nephropathy.

34. Obesity

Severe obesity can cause adaptive glomerular hyperfiltration leading to:

Secondary FSGS.

This may produce:

Significant proteinuria

and occasionally nephrotic-range proteinuria.

35. Sickle Cell Disease

Sickle cell disease can also cause:

Secondary FSGS

and progressive glomerular damage.

Patients may develop:

Proteinuria.

Albuminuria.

Progressive CKD.

36. Congenital and Genetic Causes

Some nephrotic syndromes arise from inherited abnormalities affecting:

Podocytes

or

Slit diaphragm proteins.

Examples include mutations involving proteins such as:

Nephrin.

Podocin.

These are especially important in:

Congenital or childhood nephrotic syndrome.

37. Primary versus Secondary Causes – Note Form

Primary glomerular causes:

Minimal change disease.

FSGS.

Membranous nephropathy.

Some forms of MPGN.

Secondary causes:

Diabetes mellitus.

Amyloidosis.

SLE.

Infections.

Malignancy.

Drugs.

Pregnancy-related disease such as pre-eclampsia.

Systemic disorders causing secondary glomerular injury.

38. Infection Causes – Note Form

Hepatitis B:

Classically membranous nephropathy.

Can also cause MPGN.

Hepatitis C:

Cryoglobulinaemic MPGN.

HIV:

Classically FSGS, especially collapsing FSGS.

Malaria:

Immune-mediated glomerular disease in selected forms.

Leprosy:

Immune-complex disease or secondary amyloidosis.

39. Drug Causes – Note Form

NSAIDs:

Minimal change disease.

AIN ± nephrotic syndrome.

Gold:

Membranous nephropathy.

Penicillamine:

Membranous nephropathy.

Captopril:

Rarely associated with membranous nephropathy/proteinuria.

40. Malignancy Associations – Note Form

Hodgkin lymphoma:

Minimal change disease.

Solid tumours:

Can be associated with membranous nephropathy.

Plasma-cell disorders / myeloma:

AL amyloidosis.

Monoclonal immunoglobulin deposition disease.

These may cause nephrotic syndrome.

41. Important Corrections to the Original Notes

The term:

“GN”

is very broad.

For nephrotic syndrome, the important glomerular diseases to remember specifically are:

MINIMAL CHANGE DISEASE.

FSGS.

MEMBRANOUS NEPHROPATHY.

SOME MPGN PATTERNS.

Myeloma should be understood more precisely.

Nephrotic syndrome in myeloma is particularly associated with:

AL AMYLOIDOSIS

or

MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE.

Accelerated hypertension can cause marked renal injury and proteinuria, but classic nephrotic-range proteinuria should also prompt a search for:

Underlying glomerular disease.

Important modern infectious causes to add include:

HEPATITIS C

and

HIV.

The drug association with:

Gold

and

Penicillamine

remains classically examinable, although these drugs are now used far less often.

42. High-Yield Cause–Disease Associations

Diabetes mellitus → diabetic glomerulosclerosis.

Amyloidosis → heavy proteinuria/nephrotic syndrome.

SLE → especially membranous lupus nephritis for nephrotic presentation.

HBV → membranous nephropathy.

HCV → MPGN / cryoglobulinaemic GN.

HIV → FSGS.

Hodgkin lymphoma → minimal change disease.

Solid tumour → membranous nephropathy.

NSAIDs → minimal change disease ± AIN.

Gold / penicillamine → membranous nephropathy.

Myeloma → AL amyloidosis / monoclonal deposition disease.

Key Clinical Pattern

The main causes of nephrotic syndrome can be remembered as:

PRIMARY GLOMERULAR DISEASE + SYSTEMIC DISEASE + INFECTION + MALIGNANCY + DRUGS.

The highest-yield associations are:

CHILD → MINIMAL CHANGE DISEASE.

ADULT → MEMBRANOUS NEPHROPATHY OR FSGS.

DIABETES → DIABETIC KIDNEY DISEASE.

SLE → MEMBRANOUS LUPUS NEPHRITIS.

AMYLOIDOSIS → HEAVY PROTEINURIA.

HBV → MEMBRANOUS.

HCV → MPGN.

HIV → FSGS.

HODGKIN LYMPHOMA → MINIMAL CHANGE.

NSAIDs → MINIMAL CHANGE ± AIN.

MYELOMA → AL AMYLOIDOSIS / MONOCLONAL DEPOSITION DISEASE.

Medicine – Glomerulonephritis

Glomerulonephritis (GN) refers to a group of disorders in which the renal glomeruli become inflamed or structurally damaged, leading to abnormalities of glomerular filtration.

Depending on the underlying disease, glomerular injury can produce haematuria, proteinuria, reduced glomerular filtration rate, hypertension, oedema, nephritic syndrome, nephrotic syndrome, or rapidly progressive kidney failure.

1. What Is the Glomerulus?

The glomerulus is a specialised capillary network responsible for filtering blood and producing the initial ultrafiltrate that eventually becomes urine.

The normal glomerular filtration barrier consists mainly of:

Fenestrated glomerular endothelial cells.

Glomerular basement membrane – GBM.

Podocytes with filtration slit diaphragms.

Damage to any of these structures can disturb filtration.

2. Definition of Glomerulonephritis

Glomerulonephritis describes:

Inflammatory or immune-mediated injury involving the glomeruli.

This can cause both:

Structural changes

and

Functional changes.

Not every glomerular disease is strongly inflammatory, however. For example, minimal change disease and focal segmental glomerulosclerosis are usually classified as glomerular diseases rather than classic inflammatory nephritides.

3. Structural Changes

Possible structural changes within diseased glomeruli include:

Glomerular cellular proliferation.

Infiltration by inflammatory leukocytes.

Mesangial proliferation.

Capillary-wall thickening.

Glomerular basement membrane abnormalities.

Immune-complex deposition.

Glomerular sclerosis.

Crescent formation in severe disease.

The exact pattern depends on the specific disease.

4. Cellular Proliferation

Glomerular inflammation may stimulate proliferation of:

Mesangial cells.

Endothelial cells.

Parietal epithelial cells.

In rapidly progressive glomerulonephritis, proliferation of parietal epithelial cells within Bowman’s space contributes to:

Crescent formation.

5. Leukocyte Infiltration

Inflammatory glomerular disorders may contain:

Neutrophils.

Monocytes.

Other inflammatory cells.

This is particularly prominent in some forms of:

Post-infectious glomerulonephritis.

6. Basement Membrane Changes

The GBM may become abnormal because of:

Immune deposits.

Antibody binding.

Structural thickening.

Splitting or duplication.

Examples include:

Membranous nephropathy → capillary-wall thickening with subepithelial immune deposits.

Membranoproliferative GN → duplicated or “double-contour” capillary walls.

Anti-GBM disease → antibody binding directly along the GBM.

7. Functional Changes

The most important functional abnormalities include:

Proteinuria.

Haematuria.

Reduced GFR.

Additional consequences may include:

Salt and water retention.

Oedema.

Hypertension.

Acute kidney injury.

8. Proteinuria

Proteinuria occurs when the glomerular filtration barrier becomes abnormally permeable to plasma proteins, particularly:

Albumin.

Severe protein loss can produce:

Nephrotic syndrome.

9. Haematuria

Damage to glomerular capillaries allows red blood cells to enter the urine.

Glomerular haematuria may produce:

Dysmorphic red blood cells

and

Red blood cell casts.

These strongly support a glomerular source of bleeding.

10. Reduced GFR

Inflammation, capillary obstruction, glomerular injury, or sclerosis can reduce:

Glomerular filtration rate.

The result may be:

Acute kidney injury

or, if progressive and irreversible:

Chronic kidney disease.

11. Nephritic Syndrome

A predominantly inflammatory glomerular lesion often presents as:

Nephritic syndrome.

Typical features include:

Haematuria.

RBC casts.

Proteinuria, usually less severe than nephrotic-range.

Reduced GFR.

Oliguria.

Hypertension.

Oedema.

12. Nephrotic Syndrome

A predominantly permeability-related glomerular disorder may produce:

Nephrotic syndrome.

The major features are:

Heavy proteinuria.

Hypoalbuminaemia.

Generalised oedema.

Hyperlipidaemia.

Lipiduria.

13. Major Patterns of Glomerular Disease

Important glomerular diseases include:

Minimal change disease.

Membranous nephropathy.

Focal segmental glomerulosclerosis.

IgA nephropathy.

Membranoproliferative glomerulonephritis.

Post-infectious proliferative glomerulonephritis.

Rapidly progressive crescentic glomerulonephritis.

14. Minimal Change Disease

Minimal change disease (MCD) is a glomerular disorder that classically causes:

Nephrotic syndrome.

It is particularly important in:

Children.

15. Minimal Change Disease – Epidemiology

The original note states:

“Most common.”

This needs qualification.

Minimal change disease is:

The most common cause of nephrotic syndrome in children.

It is not simply the most common type of all glomerulonephritis.

16. Minimal Change Disease – Light Microscopy

On ordinary light microscopy, the glomeruli usually appear:

Normal or nearly normal.

This explains the name:

Minimal change disease.

17. Minimal Change Disease – Electron Microscopy

Electron microscopy demonstrates:

Diffuse effacement of podocyte foot processes.

Older notes sometimes call this:

“Fusion of epithelial foot processes.”

The more accurate modern term is:

Foot-process effacement.

18. Minimal Change Disease – Immunofluorescence

Immunofluorescence is usually:

Negative or essentially normal.

This helps distinguish minimal change disease from immune-complex glomerulonephritides.

19. Minimal Change Disease – Clinical Features

Patients typically present with:

Sudden nephrotic syndrome.

Features include:

Heavy proteinuria.

Hypoalbuminaemia.

Oedema.

Renal function is often preserved, particularly in children.

20. Minimal Change Disease – Associations

Most childhood cases are idiopathic.

Possible secondary associations include:

NSAIDs.

Hodgkin lymphoma.

Some allergic or immune conditions.

21. Minimal Change Disease – Treatment

Minimal change disease is highly responsive to:

Corticosteroids.

This is especially true in children.

Therefore, rather than saying:

“Some require steroids,”

it is more accurate to say:

Corticosteroids are a major treatment, with most children showing a good response.

22. Minimal Change Disease – Prognosis

The prognosis is generally:

Excellent.

Relapses may occur, but progression to severe chronic kidney disease is uncommon in typical childhood steroid-responsive disease.

23. Minimal Change Disease – Key Pattern

Remember:

CHILD + NEPHROTIC SYNDROME + NORMAL LIGHT MICROSCOPY + PODOCYTE FOOT-PROCESS EFFACEMENT → MINIMAL CHANGE DISEASE.

24. Membranous Nephropathy

Membranous nephropathy is an important cause of:

Nephrotic syndrome in adults.

It results from immune deposits along the outer, or subepithelial, aspect of the glomerular capillary wall.

25. Membranous Nephropathy – Presentation

Patients may present with:

Nephrotic syndrome.

Heavy proteinuria without full nephrotic syndrome.

Progressive CKD in some cases.

The older term:

CRF

should be replaced with:

Chronic kidney disease – CKD.

26. Membranous Nephropathy – Pathology

The characteristic lesion is:

Diffuse thickening of glomerular capillary walls.

Immune deposits occur in a:

Subepithelial location.

27. Immune Deposits in Membranous Nephropathy

The deposits commonly contain:

IgG

and

Complement, particularly C3.

On immunofluorescence there is usually:

Granular IgG and C3 deposition along the capillary walls.

28. Membranous Nephropathy – Electron Microscopy

Electron microscopy demonstrates:

Subepithelial electron-dense deposits.

The GBM grows between the deposits, producing the classic:

“Spike and dome” appearance.

29. Primary Membranous Nephropathy

Many primary cases are caused by antibodies against podocyte antigens, most importantly:

PLA2R – phospholipase A2 receptor.

Another recognised antigen is:

THSD7A.

30. Secondary Membranous Nephropathy

Secondary causes include:

SLE.

Hepatitis B.

Some malignancies.

Certain drugs.

Therefore, secondary causes should be considered according to the patient’s age and clinical context.

31. Membranous Nephropathy – Complications

Patients with nephrotic syndrome have an increased risk of:

Venous thromboembolism.

Membranous nephropathy is particularly associated with:

Renal vein thrombosis.

32. Membranous Nephropathy – Key Pattern

Remember:

ADULT + NEPHROTIC SYNDROME + THICK GBM + SUBEPITHELIAL IgG/C3 DEPOSITS → MEMBRANOUS NEPHROPATHY.

33. Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is characterised by scarring of selected portions of selected glomeruli.

The name describes the pathology:

Focal = only some glomeruli affected.

Segmental = only part of an affected glomerulus is scarred.

Glomerulosclerosis = scarring of the glomerulus.

34. FSGS – Presentation

Patients commonly present with:

Proteinuria.

Nephrotic syndrome.

Hypertension.

Some patients also develop:

Progressive reduction in renal function.

35. Primary and Secondary FSGS

FSGS may be:

Primary.

or

Secondary.

Secondary causes include adaptive glomerular stress or injury.

36. FSGS – Important Associations

Associations include:

HIV infection.

Obesity.

Reduced nephron mass.

Sickle cell disease.

Some drugs.

Genetic podocyte disorders.

37. FSGS – Pathology

Light microscopy shows:

Segmental areas of sclerosis and hyalinosis in some glomeruli.

Electron microscopy often demonstrates:

Podocyte foot-process effacement.

38. FSGS – Prognosis

FSGS is generally less steroid-responsive than minimal change disease and has a greater risk of progression to:

Chronic kidney disease

and

ESKD.

39. FSGS – Key Pattern

Remember:

FOCAL + SEGMENTAL SCARRING + PROTEINURIA/NEPHROTIC SYNDROME → FSGS.

40. IgA Nephropathy

IgA nephropathy, also known as:

Berger disease,

is an immune-mediated glomerular disorder characterised by deposition of:

IgA within the glomerular mesangium.

It is one of the most common primary glomerular diseases worldwide.

41. IgA Nephropathy – Age

IgA nephropathy commonly affects:

Children, adolescents, and young adults,

although it may occur at any age.

42. IgA Nephropathy – Classic Presentation

The classic presentation is:

Visible haematuria occurring during or shortly after an upper respiratory tract infection.

This is sometimes called:

Synpharyngitic haematuria.

43. Timing after Pharyngitis

A very important distinction is that IgA nephropathy typically causes haematuria:

At the same time as, or within a few days of, a respiratory infection.

This differs from post-streptococcal glomerulonephritis, which usually occurs after a latent interval.

44. IgA Nephropathy – Other Presentations

Patients may also have:

Persistent microscopic haematuria.

Proteinuria.

Hypertension.

Progressive CKD.

Some develop nephritic syndrome.

45. IgA Nephropathy – Pathology

Light microscopy often demonstrates:

Mesangial proliferation.

Immunofluorescence demonstrates:

Mesangial IgA deposition.

C3 may also be present.

46. IgA Nephropathy – Prognosis

The course is highly variable.

Some patients have mild disease for decades, while others develop:

Progressive CKD and ESKD.

Risk factors for progression include:

Persistent proteinuria.

Hypertension.

Reduced GFR.

Significant chronic changes on biopsy.

47. IgA Nephropathy – Key Pattern

Remember:

YOUNG PERSON + HAEMATURIA DURING/IMMEDIATELY AFTER PHARYNGITIS + MESANGIAL IgA → IgA NEPHROPATHY.

48. Membranoproliferative Glomerulonephritis

The older term:

Mesangiocapillary glomerulonephritis

is commonly replaced by:

Membranoproliferative glomerulonephritis – MPGN.

MPGN describes a characteristic pattern of glomerular injury rather than a single disease.

49. MPGN – Presentation

Patients may present with:

Nephritic syndrome.

Nephrotic syndrome.

Mixed nephritic-nephrotic features.

Proteinuria.

Haematuria.

Hypertension.

Reduced renal function.

50. MPGN – Pathology

There is typically:

Mesangial proliferation.

Endocapillary proliferation.

Capillary-wall remodelling.

The GBM may show:

Duplication or splitting.

This produces the classic:

Double-contour or “tram-track” appearance.

51. Why the Double Contour Occurs

The double contour results from:

New basement membrane formation around deposits and interposed mesangial cells.

This gives the capillary wall a duplicated appearance on microscopy.

52. Modern Classification of MPGN

Older classifications divided MPGN into:

Type I.

Type II.

Type III.

Modern classification focuses more on the underlying mechanism:

Immune-complex-mediated MPGN.

or

Complement-mediated disease / C3 glomerulopathy.

53. C3 Nephritic Factor

The original note states:

“60% have C3 nephritic factor.”

This should not be applied to all MPGN.

C3 nephritic factor is particularly associated with abnormalities of the alternative complement pathway, especially:

C3 glomerulopathy

including the disorder historically known as:

Dense deposit disease.

54. Complement in MPGN

Complement levels may be:

Low,

especially in complement-mediated forms and some immune-complex forms.

Therefore, hypocomplementaemia is an important diagnostic clue.

55. Causes of Immune-Complex MPGN

Possible causes include:

Chronic infections.

Hepatitis B.

Hepatitis C.

Autoimmune disease.

Monoclonal immunoglobulin disorders.

56. MPGN – Key Pattern

Remember:

NEPHRITIC + NEPHROTIC FEATURES + LOW COMPLEMENT + DOUBLE-CONTOUR/TRAM-TRACK GBM → THINK MPGN.

57. Post-Infectious Glomerulonephritis

The older term:

Diffuse proliferative glomerulonephritis

may describe the histological pattern seen in:

Post-infectious glomerulonephritis.

Classically this follows infection with certain strains of:

Group A Streptococcus.

58. Post-Streptococcal Glomerulonephritis

Post-streptococcal glomerulonephritis, or:

PSGN,

typically develops after:

Streptococcal pharyngitis

or

Streptococcal skin infection.

59. Timing after Infection

Unlike IgA nephropathy, PSGN occurs after a:

Latent interval.

Classically:

About 1–3 weeks after pharyngitis.

The interval after skin infection may be somewhat longer.

60. PSGN – Typical Age

PSGN is particularly common in:

Children.

However, adults can also develop it and may experience more severe disease.

61. PSGN – Presentation

The typical presentation is:

Acute nephritic syndrome.

Features include:

Tea- or cola-coloured urine.

Haematuria.

Oedema.

Hypertension.

Reduced urine output.

AKI.

Mild-to-moderate proteinuria.

62. Complement in PSGN

A classic laboratory finding is:

Low serum C3.

Complement usually returns toward normal over several weeks.

Persistent low complement should prompt consideration of an alternative diagnosis.

63. Evidence of Recent Streptococcal Infection

Tests may include:

ASO titre – antistreptolysin O.

However, after streptococcal skin infection, ASO may be less reliable.

Another useful antibody is:

Anti-DNase B.

64. PSGN – Light Microscopy

Light microscopy typically shows:

Diffuse endocapillary hypercellularity.

There may be numerous:

Neutrophils.

This produces a proliferative glomerulonephritis.

65. PSGN – Immunofluorescence

Immunofluorescence typically shows:

Granular IgG and C3 deposition.

This is often described as:

“Lumpy-bumpy” staining.

66. PSGN – Electron Microscopy

Electron microscopy classically demonstrates:

Subepithelial immune-complex deposits.

These are known as:

Subepithelial humps.

67. PSGN – Prognosis

Children usually have an:

Excellent prognosis.

Adults generally have a greater risk of:

Persistent renal impairment.

Treatment is mainly supportive, including management of:

Fluid overload.

Hypertension.

Electrolyte abnormalities.

68. PSGN – Key Pattern

Remember:

CHILD + NEPHRITIC SYNDROME 1–3 WEEKS AFTER STREP THROAT + LOW C3 → PSGN.

69. IgA Nephropathy versus PSGN – Note Form

IgA nephropathy:

Haematuria occurs during or immediately after respiratory infection.

Mesangial IgA deposition.

Complement usually normal.

Post-streptococcal GN:

Haematuria usually occurs after a latent interval.

Often 1–3 weeks after pharyngitis.

Low C3.

Granular IgG/C3.

Subepithelial humps.

70. Rapidly Progressive Glomerulonephritis

Rapidly progressive glomerulonephritis (RPGN) is a clinical syndrome characterised by:

Rapid deterioration of renal function over days to weeks, sometimes extending over several months,

together with:

Crescent formation in the glomeruli.

It is therefore also called:

Crescentic glomerulonephritis.

71. Clinical Features of RPGN

Patients typically have:

Haematuria.

Proteinuria.

RBC casts.

Rapidly rising creatinine.

Reduced urine output.

Hypertension.

Without treatment, severe disease may progress rapidly to:

ESKD.

72. Crescent Formation

Crescents form in:

Bowman’s space

when severe glomerular capillary-wall injury allows:

Fibrin and inflammatory mediators

to enter the urinary space.

This stimulates proliferation of:

Parietal epithelial cells

and recruitment of inflammatory cells.

73. RPGN Type I – Anti-GBM Disease

Type I RPGN is caused by:

Anti-GBM antibodies.

The classic disease is:

Goodpasture / anti-GBM disease.

Immunofluorescence shows:

Linear IgG deposition along the GBM.

Pulmonary haemorrhage may occur.

74. RPGN Type II – Immune-Complex Disease

Type II RPGN results from:

Immune-complex deposition.

Causes include:

SLE / lupus nephritis.

Post-infectious GN.

IgA nephropathy.

Other immune-complex diseases may also produce severe crescentic disease.

Immunofluorescence is usually:

Granular.

75. RPGN Type III – Pauci-Immune Disease

Type III RPGN is usually caused by:

ANCA-associated vasculitis.

Examples include:

Granulomatosis with polyangiitis – GPA, formerly Wegener granulomatosis.

Microscopic polyangiitis.

Eosinophilic granulomatosis with polyangiitis in selected cases.

76. Pauci-Immune Meaning

Pauci-immune means:

Little or no immune deposition is seen on immunofluorescence.

This is typical of:

ANCA-associated crescentic GN.

77. RPGN – Investigation

Important investigations include:

Urinalysis.

Urine microscopy.

Creatinine and eGFR.

Anti-GBM antibodies.

ANCA.

ANA and anti-dsDNA.

Complement levels.

Infection studies where appropriate.

A:

Renal biopsy

is usually central to establishing the exact type.

78. RPGN – Treatment

RPGN is a:

Nephrological emergency.

Treatment depends on the cause but may involve:

High-dose corticosteroids.

Cyclophosphamide or rituximab.

Plasma exchange in selected anti-GBM disease and certain other specific situations.

Treatment of underlying infection where relevant.

79. Dialysis in RPGN

Severe AKI may require:

Temporary or long-term dialysis.

However, early recognition and treatment can sometimes preserve significant renal function.

80. Kidney Transplantation

Some patients who develop irreversible ESKD may eventually require:

Kidney transplantation.

Transplant timing depends on the underlying disease being appropriately controlled.

81. Prognosis of RPGN

Prognosis depends strongly on:

Renal function at presentation.

Severity of crescent formation.

Degree of chronic scarring.

Underlying cause.

Speed of treatment.

Patients presenting with very advanced, dialysis-dependent disease generally have a lower chance of renal recovery.

82. Major Glomerular Disorders – Note Form

Minimal change disease:

Most common cause of childhood nephrotic syndrome.

Light microscopy nearly normal.

Electron microscopy shows podocyte foot-process effacement.

Usually steroid responsive.

Good prognosis.

Membranous nephropathy:

Important cause of adult nephrotic syndrome.

Diffuse capillary-wall thickening.

Subepithelial IgG/C3 deposits.

Spike-and-dome appearance.

PLA2R frequently involved in primary disease.

FSGS:

Focal and segmental glomerular scarring.

Proteinuria or nephrotic syndrome.

Hypertension may occur.

Higher risk of progressive CKD than typical minimal change disease.

IgA nephropathy:

Often young patients.

Visible haematuria during or immediately after respiratory infection.

Mesangial proliferation.

Mesangial IgA deposition.

MPGN:

May produce nephritic and nephrotic features.

Low complement may occur.

Mesangial/endocapillary proliferation.

Double-contour or tram-track appearance.

Modern classification divides disease into immune-complex and complement-mediated forms.

Post-streptococcal GN:

Acute nephritic syndrome.

Usually follows streptococcal infection after a latent period.

Low C3.

ASO or anti-DNase B evidence of recent infection.

Granular IgG/C3.

Subepithelial humps.

Rapidly progressive GN:

Rapid renal deterioration.

Crescent formation.

Type I = anti-GBM.

Type II = immune complex.

Type III = pauci-immune / ANCA associated.

Requires urgent investigation and treatment.

83. Important Corrections to the Original Notes

The statement:

“Minimal change GN is the most common”

should be changed to:

Minimal change disease is the most common cause of nephrotic syndrome in children.

The electron microscopy finding in minimal change disease is better called:

PODOCYTE FOOT-PROCESS EFFACEMENT

rather than simply:

“Fusion.”

The older term:

Mesangiocapillary GN

is now more commonly called:

MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS – MPGN.

The statement:

“60% have C3 nephritic factor”

should not be applied to all MPGN.

C3 nephritic factor is particularly associated with:

C3 glomerulopathy / alternative complement pathway dysregulation.

The older term:

Wegener’s granulomatosis

is now:

GRANULOMATOSIS WITH POLYANGIITIS – GPA.

The older terms:

ARF

and

ESRF

are better replaced with:

AKI – acute kidney injury

and

ESKD – end-stage kidney disease.

84. High-Yield Immunofluorescence Patterns

Minimal change disease:

Usually negative.

Membranous nephropathy:

Granular IgG and C3 along capillary walls.

IgA nephropathy:

Mesangial IgA deposition.

Post-infectious GN:

Granular IgG and C3.

Anti-GBM disease:

Linear IgG along GBM.

ANCA-associated GN:

Pauci-immune.

Little or no immune deposition.

85. High-Yield Electron Microscopy Patterns

Minimal change disease:

Foot-process effacement.

Membranous nephropathy:

Subepithelial deposits.

Spike-and-dome pattern.

Post-streptococcal GN:

Subepithelial humps.

MPGN:

GBM duplication / double contour.

Key Clinical Pattern

For nephrotic disease, remember:

MINIMAL CHANGE → CHILD + FOOT-PROCESS EFFACEMENT.

MEMBRANOUS → ADULT + SUBEPITHELIAL DEPOSITS + THICK GBM.

FSGS → FOCAL SEGMENTAL SCARRING + NEPHROTIC PROTEINURIA.

For haematuric/nephritic disease, remember:

IgA NEPHROPATHY → HAEMATURIA DURING OR IMMEDIATELY AFTER PHARYNGITIS.

PSGN → HAEMATURIA AFTER A LATENT PERIOD + LOW C3.

For rapidly progressive disease, remember:

TYPE I RPGN → ANTI-GBM → LINEAR IgG.

TYPE II RPGN → IMMUNE COMPLEX → GRANULAR DEPOSITS.

TYPE III RPGN → ANCA → PAUCI-IMMUNE.

The overall clinical clue is:

HAEMATURIA + PROTEINURIA + RBC CASTS + REDUCED GFR → THINK GLOMERULAR DISEASE.

Medicine – Goodpasture Syndrome

Goodpasture syndrome is an autoimmune pulmonary–renal syndrome caused by antibodies directed against the glomerular basement membrane (GBM). The same antibodies can also attack basement membranes in the pulmonary alveolar capillaries, producing the classic combination of:

Rapidly progressive glomerulonephritis + pulmonary haemorrhage.

The more precise modern term for the renal disease is:

Anti-GBM disease.

When anti-GBM disease causes both renal and pulmonary involvement, the term Goodpasture syndrome is commonly used.

1. Autoantibody Against the GBM

The disease is caused by:

Anti-glomerular basement membrane antibodies.

These antibodies are directed mainly against the:

α3 chain of type IV collagen

within basement membranes.

The most important target is the:

NC1 domain of the α3 chain of type IV collagen.

2. Sites of Antibody Attack

The antibodies bind to basement membranes in:

Renal glomerular capillaries.

and

Pulmonary alveolar capillaries.

This explains why the two major organs involved are:

Kidneys

and

Lungs.

3. Pulmonary–Renal Syndrome

Goodpasture syndrome is one of the classical causes of:

Pulmonary–renal syndrome.

This means the simultaneous presence of:

Pulmonary haemorrhage

and

Glomerulonephritis.

Other important causes of pulmonary–renal syndrome include:

ANCA-associated vasculitis, especially granulomatosis with polyangiitis and microscopic polyangiitis.

4. Renal Pathology

The renal lesion is typically:

Rapidly progressive glomerulonephritis, or RPGN.

This causes a rapid decline in renal function over:

Days to weeks.

5. Crescentic Glomerulonephritis

On renal biopsy, anti-GBM disease typically produces:

Crescentic glomerulonephritis.

Crescents form in Bowman’s space as a result of severe glomerular capillary injury.

These crescents are composed of:

Proliferating parietal epithelial cells

and

Inflammatory cells.

6. Why Crescents Matter

Crescent formation indicates:

Severe glomerular injury.

The greater the proportion of glomeruli containing crescents, the worse the renal prognosis tends to be.

7. Immunofluorescence

The classic renal biopsy finding is:

Linear deposition of IgG along the GBM.

Complement, particularly:

C3,

may also be deposited.

This is a very high-yield pathological finding.

8. Linear versus Granular Immunofluorescence

Remember:

Anti-GBM disease → linear IgG deposition.

By contrast:

Immune-complex glomerulonephritis → granular deposition.

This distinction is extremely useful in exams.

9. Pulmonary Haemorrhage

Anti-GBM antibodies can also damage the pulmonary alveolar basement membrane.

This causes:

Diffuse alveolar haemorrhage.

The patient may develop:

Haemoptysis.

Breathlessness.

Hypoxaemia.

Anaemia.

10. Haemoptysis

One of the classic presenting symptoms is:

Haemoptysis.

This may range from:

Blood-streaked sputum

to

Massive pulmonary haemorrhage.

However, absence of visible haemoptysis does not completely exclude alveolar haemorrhage.

11. Breathlessness

Pulmonary haemorrhage may cause:

Acute dyspnoea.

This results from:

Blood filling the alveoli.

Impaired gas exchange.

Hypoxaemia.

Severe cases may progress to:

Respiratory failure.

12. Anaemia

Repeated or severe pulmonary haemorrhage can produce:

Iron-deficiency or acute blood-loss anaemia.

Therefore, a falling haemoglobin level may be an important clue.

13. Haematuria

Renal involvement commonly causes:

Microscopic haematuria

or sometimes:

Visible haematuria.

Urinalysis often shows features of glomerular bleeding.

14. Dysmorphic Red Cells

Because bleeding originates from the glomeruli, urine microscopy may demonstrate:

Dysmorphic red blood cells.

These support:

Glomerular haematuria.

15. Red Blood Cell Casts

A particularly important urinary finding is:

Red blood cell casts.

These strongly suggest:

Glomerulonephritis.

Therefore:

Haematuria + RBC casts + rapidly rising creatinine → think rapidly progressive GN.

16. Proteinuria

Proteinuria may occur, usually:

Mild to moderate.

It is not usually the dominant feature compared with haematuria and rapidly declining renal function.

17. Progressive Renal Failure

Renal function can deteriorate very rapidly.

Patients may develop:

Acute kidney injury.

In severe cases this can progress rapidly to:

Dialysis-dependent kidney failure.

Older notes may call this:

Progressive renal failure.

The modern terminology is more appropriately:

Rapidly progressive AKI due to crescentic glomerulonephritis.

18. Clinical Pattern

The classic presentation is:

Haemoptysis + haematuria + rapidly rising creatinine.

This combination should immediately raise concern for:

Pulmonary–renal syndrome.

19. Age and Epidemiology

Anti-GBM disease is rare.

It can occur at different ages, but classical teaching recognises peaks in:

Younger adults

and

Older adults.

Pulmonary haemorrhage is more commonly seen in younger patients.

20. Environmental Triggers

Pulmonary haemorrhage may be promoted by factors that damage the alveolar basement membrane.

Important associations include:

Cigarette smoking.

Hydrocarbon exposure.

Respiratory infection.

Smoking is particularly important because it can increase pulmonary involvement.

21. Diagnosis – Anti-GBM Antibodies

A key diagnostic test is:

Serum anti-GBM antibody testing.

A positive result in the appropriate clinical setting strongly supports the diagnosis.

22. Renal Biopsy

Renal biopsy is important when feasible because it can:

Confirm the diagnosis.

Assess the severity of glomerular injury.

Estimate renal prognosis.

The key features are:

Crescentic GN

and

Linear IgG staining along the GBM.

23. Chest Imaging

Chest X-ray or CT may demonstrate:

Bilateral diffuse alveolar infiltrates

due to pulmonary haemorrhage.

These changes can resemble:

Pulmonary oedema.

Pneumonia.

Therefore, the clinical context is essential.

24. Bronchoscopy

In selected cases, bronchoscopy with bronchoalveolar lavage can help confirm:

Diffuse alveolar haemorrhage.

Sequential lavage samples may become increasingly blood-stained.

25. ANCA Testing

Some patients with anti-GBM disease also have:

ANCA antibodies.

These are called:

Double-positive patients.

This overlap is clinically important because the disease may behave partly like:

ANCA-associated vasculitis.

26. Double-Positive Disease

Patients positive for both:

Anti-GBM antibodies

and

ANCA

may have a greater tendency to relapse than classic isolated anti-GBM disease.

Therefore, their long-term management may require closer follow-up.

27. Treatment Is an Emergency

Goodpasture syndrome is a:

Medical emergency.

Treatment should begin rapidly because ongoing antibody-mediated injury can cause irreversible:

Kidney failure

and

Life-threatening pulmonary haemorrhage.

28. Three Main Components of Treatment

The traditional and still important treatment combination is:

Plasma exchange.

Corticosteroids.

Cyclophosphamide.

Each has a different role.

29. Plasma Exchange

Plasma exchange, or plasmapheresis, removes circulating:

Anti-GBM antibodies

from the blood.

It is usually performed repeatedly until antibody levels become undetectable or sufficiently suppressed.

30. Why Plasma Exchange Is Important

Plasma exchange reduces the amount of antibody available to attack:

Glomerular

and

Alveolar basement membranes.

It is particularly important when there is:

Pulmonary haemorrhage

or

Potentially recoverable renal disease.

31. Corticosteroids

High-dose:

Corticosteroids

are used to suppress the inflammatory response.

Treatment often begins with:

High-dose intravenous or oral glucocorticoids

depending on severity and local protocol.

32. Cyclophosphamide

Cyclophosphamide suppresses the immune cells producing the pathogenic antibodies.

Its role is to:

Stop further anti-GBM antibody production.

Therefore:

Plasma exchange removes existing antibody

while

Cyclophosphamide reduces new antibody production.

33. How the Three Treatments Work Together

Remember the mechanism:

Plasma exchange → removes anti-GBM antibody.

Cyclophosphamide → stops new antibody production.

Steroids → suppress inflammatory tissue injury.

This is the classic therapeutic strategy.

34. Supportive Management

Patients may also require:

Oxygen therapy.

Blood transfusion for severe anaemia.

Mechanical ventilation for respiratory failure.

Treatment of electrolyte abnormalities.

Fluid management.

Dialysis if severe AKI develops.

35. Dialysis

Dialysis may be required for:

Severe hyperkalaemia.

Metabolic acidosis.

Fluid overload.

Uraemic complications.

Severe renal failure.

However, the requirement for dialysis at presentation has major prognostic implications.

36. Prognosis

The original statement is correct:

Prognosis depends strongly on renal function at presentation.

Patients who begin treatment before severe irreversible glomerular destruction have a much better chance of renal recovery.

37. Poor Renal Prognostic Features

Poor renal recovery is more likely when the patient presents with:

Very high serum creatinine.

Oliguria or anuria.

Dialysis dependence.

A very high percentage of crescents on biopsy.

Extensive glomerular scarring.

38. Importance of Dialysis Dependence at Presentation

If a patient is already:

Dialysis dependent

with extensive crescent formation and irreversible glomerular destruction, recovery of kidney function may be unlikely.

However, treatment may still be urgently required if there is:

Active pulmonary haemorrhage.

39. Pulmonary Prognosis

Pulmonary haemorrhage can be dramatic and life-threatening, but it is often:

More reversible than the renal damage

if treated promptly.

This is because glomerular scarring can become permanent, whereas alveolar haemorrhage may resolve after antibody suppression.

40. Relapse

Classic isolated anti-GBM disease is generally:

Monophasic.

Relapse is uncommon once anti-GBM antibodies disappear.

This differs from:

ANCA-associated vasculitis,

which has a greater tendency to relapse.

41. Kidney Transplantation

Patients who progress to ESKD may eventually undergo:

Kidney transplantation.

Transplantation is generally delayed until:

Anti-GBM antibodies have remained undetectable for an appropriate period.

This reduces the risk of recurrent disease in the transplanted kidney.

42. Goodpasture Syndrome – Note Form

Autoantibody:

Anti-GBM antibody.

Target:

α3 chain of type IV collagen.

Organs affected:

Kidneys.

Lungs.

Renal lesion:

Rapidly progressive crescentic glomerulonephritis.

Pulmonary lesion:

Diffuse alveolar haemorrhage.

Clinical features:

Haemoptysis.

Breathlessness.

Pulmonary haemorrhage.

Haematuria.

Rapidly rising creatinine.

AKI.

Possible dialysis dependence.

Urine:

Dysmorphic RBCs.

RBC casts.

Proteinuria may occur.

Serology:

Anti-GBM antibodies.

Check ANCA because double-positive disease can occur.

Renal biopsy:

Crescentic glomerulonephritis.

Immunofluorescence:

Linear IgG deposition along GBM.

Treatment:

Plasma exchange.

High-dose corticosteroids.

Cyclophosphamide.

Supportive care.

Dialysis if required.

43. Goodpasture versus ANCA Vasculitis – Note Form

Goodpasture / anti-GBM disease:

Anti-GBM antibodies.

Linear IgG on immunofluorescence.

Pulmonary haemorrhage + RPGN.

Relapse usually uncommon.

ANCA-associated vasculitis:

ANCA may be positive.

Usually pauci-immune glomerulonephritis.

Often associated with systemic vasculitic features.

Relapse is more common.

44. Important Corrections to the Original Notes

The original note states:

“Autoantibody to GBM.”

This is correct but can be made more precise:

Anti-GBM antibodies target the α3 chain of type IV collagen.

The renal lesion:

Rapidly progressive GN

is more specifically:

CRESCENTIC GLOMERULONEPHRITIS.

The characteristic biopsy immunofluorescence finding should be added:

LINEAR IgG DEPOSITION ALONG THE GBM.

The older description:

“Progressive renal failure”

is better understood as:

Rapidly progressive AKI due to crescentic glomerulonephritis, potentially progressing to ESKD.

Key Clinical Pattern

Remember:

GOODPASTURE = LUNG + KIDNEY.

The classic presentation is:

HAEMOPTYSIS + HAEMATURIA + RAPIDLY RISING CREATININE.

Pathology:

ANTI-GBM ANTIBODY → CRESCENTIC RPGN + PULMONARY ALVEOLAR HAEMORRHAGE.

Biopsy:

LINEAR IgG ALONG THE GBM.

Treatment:

PLASMA EXCHANGE + STEROIDS + CYCLOPHOSPHAMIDE.

And prognosis:

THE WORSE THE RENAL FUNCTION AT PRESENTATION, ESPECIALLY IF ALREADY DIALYSIS-DEPENDENT WITH EXTENSIVE CRESCENTS, THE LOWER THE CHANCE OF RENAL RECOVERY.

Medicine – Acute Interstitial Nephritis

Acute interstitial nephritis (AIN) is an inflammatory disorder affecting primarily the renal interstitium and tubules. It is an important and potentially reversible cause of acute kidney injury (AKI).

The most common cause is a drug-induced immune or hypersensitivity reaction, although infections, autoimmune disorders, and other systemic diseases can also produce tubulointerstitial inflammation.

1. Site of Renal Injury

AIN primarily affects the:

Renal interstitium

and

Renal tubules.

This distinguishes it from glomerulonephritis, in which the principal inflammatory injury occurs within the:

Glomeruli.

2. Pathophysiology

In many cases, particularly drug-induced AIN, the offending agent triggers an:

Immune-mediated inflammatory response.

Inflammatory cells infiltrate the renal interstitium and produce:

Interstitial oedema.

Tubular inflammation.

Tubular dysfunction.

This reduces renal function and may cause AKI.

3. Drug-Induced Acute Interstitial Nephritis

Drugs are among the most important causes of AIN.

The reaction is generally:

Idiosyncratic and immune mediated

rather than simply the result of dose-dependent drug toxicity.

Therefore, AIN can occur even at ordinary therapeutic doses.

4. Clinical Presentation

The original notes list:

Mild renal impairment

and

Hypertension.

However, the presentation is considerably more variable.

The most important renal manifestation is:

Acute kidney injury.

The rise in serum creatinine may be mild or severe.

5. Acute Kidney Injury

Patients typically develop:

Increasing serum creatinine

with a reduction in:

GFR.

The onset may occur days to weeks after exposure to the causative drug, although the timing varies considerably between medications and previous exposures.

6. Urinary Features

Urinalysis may demonstrate:

Sterile pyuria.

Mild-to-moderate proteinuria.

Microscopic haematuria.

White blood cell casts.

These findings reflect inflammation of the tubulointerstitial compartment.

7. Sterile Pyuria

A particularly useful clue is:

Sterile pyuria.

This means:

White blood cells in the urine despite a negative routine bacterial urine culture.

AIN is therefore an important cause of sterile pyuria.

8. White Cell Casts

Inflammatory white cells may enter the renal tubules and form:

White blood cell casts.

These support an inflammatory process within the kidney rather than simple contamination of the urine.

However, WBC casts are not specific to AIN and can also occur in disorders such as:

Pyelonephritis.

9. Proteinuria

Proteinuria is usually:

Mild or moderate.

Heavy nephrotic-range proteinuria is less typical.

An important exception is:

NSAID-associated AIN,

which can occasionally be associated with substantial or nephrotic-range proteinuria, sometimes alongside minimal-change disease.

10. Haematuria

Patients may develop:

Microscopic haematuria.

However, prominent glomerular haematuria with numerous dysmorphic red cells and red-cell casts should raise suspicion for:

Glomerulonephritis

rather than uncomplicated AIN.

11. Hypertension

Hypertension can occur, particularly when there is:

Sodium and water retention

from impaired renal function.

However, hypertension is not the defining presentation.

The more important pattern is:

Recent drug exposure + unexplained AKI + inflammatory urinary findings.

12. Hypersensitivity Features

Drug-induced AIN may produce systemic manifestations of hypersensitivity, including:

Fever.

Skin rash.

Peripheral eosinophilia.

The traditional teaching describes a triad of:

Fever + rash + eosinophilia.

13. The Classic Triad Is Often Absent

An important clinical point is that the complete hypersensitivity triad occurs in only a minority of patients.

Therefore:

No fever, rash, or eosinophilia does NOT exclude AIN.

This is particularly important because many patients present only with:

Unexplained AKI.

14. Eosinophilia

Peripheral blood:

Eosinophilia

may support drug-induced AIN, particularly when accompanied by rash or fever.

However, it is neither sufficiently sensitive nor specific to establish the diagnosis.

15. Urinary Eosinophils

Older teaching often emphasised:

Eosinophils in the urine.

However, eosinophiluria has poor diagnostic accuracy.

Therefore:

Urinary eosinophils should not be relied upon to diagnose or exclude AIN.

16. Drug Causes

A very wide range of drugs can cause AIN.

Important groups include:

Antibiotics.

NSAIDs.

Proton-pump inhibitors.

Certain diuretics.

Some anticonvulsants and other medications.

A careful medication history is essential.

17. Penicillins

Penicillins are classical causes of drug-induced AIN.

Examples include:

Methicillin historically.

Amoxicillin.

Other beta-lactam antibiotics.

The mechanism is usually immune mediated.

18. Sulfonamides

Sulfonamide-containing drugs are another traditional association.

They can produce:

Hypersensitivity reactions

including tubulointerstitial inflammation.

19. NSAIDs

Non-steroidal anti-inflammatory drugs (NSAIDs) are important causes of AIN.

NSAID-associated disease may differ from the classic hypersensitivity pattern because:

Fever, rash, and eosinophilia may be less prominent.

Proteinuria may be more substantial.

20. Proton-Pump Inhibitors

An important modern addition is:

Proton-pump inhibitors (PPIs).

Examples include:

Omeprazole.

Lansoprazole.

Pantoprazole.

PPI-associated AIN may develop relatively insidiously and without obvious hypersensitivity symptoms.

21. Other Antibiotics

AIN may occur with several antimicrobial drugs, including:

Cephalosporins.

Rifampicin.

Fluoroquinolones.

and others.

Therefore, the entire medication history should be reviewed rather than looking only for penicillin exposure.

22. Infections

AIN can also occur in association with infection.

The inflammatory process may result from:

Direct infection

or

An immune response associated with infection.

23. CMV

Cytomegalovirus (CMV) can be associated with tubulointerstitial nephritis, particularly in:

Immunocompromised patients.

The clinical context is therefore important.

24. Leptospirosis

Leptospirosis can cause significant renal involvement, including:

Tubulointerstitial nephritis

and

Acute kidney injury.

Patients may also have:

Fever.

Myalgia.

Jaundice in severe disease.

25. Mycobacterial Infection

Mycobacterial disease, particularly:

Tuberculosis,

can involve the kidney and cause chronic granulomatous tubulointerstitial inflammation.

A classic urinary clue is:

Persistent sterile pyuria.

26. Autoimmune Causes

Several systemic immune-mediated disorders can cause interstitial nephritis.

Important examples include:

Sjögren syndrome.

Sarcoidosis.

Systemic lupus erythematosus.

IgG4-related disease.

27. Sjögren Syndrome

Sjögren syndrome is an important cause of chronic or acute tubulointerstitial nephritis.

Tubular dysfunction may produce:

Distal renal tubular acidosis.

Therefore:

Sjögren + metabolic acidosis + alkaline urine/hypokalaemia → consider distal RTA from tubulointerstitial disease.

28. Sarcoidosis

Sarcoidosis can produce:

Granulomatous interstitial nephritis.

It may also cause renal problems through:

Hypercalcaemia and hypercalciuria

due to increased vitamin D activation by granulomas.

29. SLE

Systemic lupus erythematosus (SLE) can involve the renal interstitium.

However, the classic and much more important renal manifestation of SLE is:

Immune-complex glomerulonephritis – lupus nephritis.

Therefore, SLE should not be thought of primarily as a typical cause of isolated AIN.

30. Goodpasture Syndrome – Important Correction

The original notes list:

Goodpasture’s syndrome

as a cause of AIN.

This is not the typical renal lesion.

Goodpasture disease, or anti-GBM disease, primarily causes:

Rapidly progressive glomerulonephritis

due to antibodies directed against the glomerular basement membrane.

It may occur with:

Pulmonary haemorrhage.

Therefore:

GOODPASTURE / ANTI-GBM DISEASE → GLOMERULONEPHRITIS, NOT CLASSIC AIN.

31. TINU Syndrome

Another important cause is:

Tubulointerstitial nephritis and uveitis syndrome (TINU).

This combines:

Acute interstitial nephritis

with

Uveitis.

It is particularly important in younger patients.

32. Kidney Biopsy

AIN can often be suspected clinically, particularly when AKI follows exposure to a known causative drug.

However, when the diagnosis is uncertain or kidney dysfunction is severe or persistent:

Renal biopsy

may be considered.

33. Histology

The characteristic biopsy findings include:

Interstitial inflammatory cell infiltration.

Interstitial oedema.

Tubulitis.

The glomeruli are often relatively preserved.

34. Tubulitis

Tubulitis means inflammatory cells infiltrating the tubular epithelium.

This is an important histological feature of:

Tubulointerstitial inflammation.

35. Eosinophils on Biopsy

In drug-induced disease, the interstitial infiltrate may contain:

Eosinophils.

However, eosinophils are not always present and are not unique to AIN.

The infiltrate may also contain:

Lymphocytes.

Monocytes.

Plasma cells.

36. Granulomatous Interstitial Nephritis

Granulomas may occur in selected causes of interstitial nephritis.

Important associations include:

Sarcoidosis.

Tuberculosis.

Certain drugs.

Therefore, granulomatous inflammation on biopsy changes the differential diagnosis.

37. Treatment – Remove the Cause

The most important treatment of drug-induced AIN is:

Immediately stop the suspected offending drug whenever possible.

Early withdrawal reduces continued inflammatory injury and improves the likelihood of renal recovery.

38. Supportive Treatment

Patients should also receive appropriate management of AKI.

This may include:

Monitoring renal function.

Monitoring potassium and other electrolytes.

Maintaining appropriate fluid balance.

Avoiding additional nephrotoxic drugs.

Adjusting drug doses for renal function.

39. Corticosteroids

The original note states:

“Some require a small dose of steroids.”

This needs qualification.

Corticosteroids may be considered in selected patients with:

Drug-induced AIN and significant or persistent renal dysfunction, particularly when renal function fails to improve promptly after withdrawal of the causative drug.

40. Steroid Evidence

Steroids are not automatically required in every case.

Their use depends on factors such as:

Severity of AKI.

Biopsy findings.

Likelihood of drug-induced disease.

Response after drug withdrawal.

Risk of steroid treatment.

If steroids are appropriate, early treatment may be more useful than waiting until extensive fibrosis develops.

41. Treat Infection Appropriately

If AIN is caused by an infection, treatment should target:

The underlying infection.

Immunosuppression should not simply be given without considering whether active infection is present.

42. Dialysis

Severe AIN can occasionally produce AKI requiring:

Temporary dialysis.

Indications are the same as for other forms of severe AKI, such as refractory:

Hyperkalaemia.

Metabolic acidosis.

Fluid overload.

Uraemic complications.

The need for dialysis does not necessarily mean that renal failure will be permanent.

43. Prognosis

The original statement that:

Most patients recover completely

is broadly reassuring but somewhat optimistic.

Many patients experience substantial renal recovery, particularly when the offending drug is identified and stopped early.

However, recovery is not always complete.

44. Incomplete Recovery

Some patients are left with:

Reduced GFR

or

Chronic kidney disease.

The risk of incomplete recovery increases with:

Delayed diagnosis.

Prolonged exposure to the offending drug.

Severe initial kidney injury.

Older age.

Interstitial fibrosis on biopsy.

45. Why Early Diagnosis Matters

Persistent inflammation can eventually lead to:

Tubular atrophy

and

Interstitial fibrosis.

Once significant fibrosis has developed, renal damage becomes less reversible.

Therefore:

Early recognition + removal of cause → greater chance of renal recovery.

46. Acute Interstitial Nephritis – Note Form

Definition:

Inflammatory disorder of the renal interstitium and tubules.

Major renal presentation:

Acute kidney injury.

Urinalysis:

Sterile pyuria.

Mild-to-moderate proteinuria.

Microscopic haematuria.

White blood cell casts.

Classic hypersensitivity features:

Fever.

Rash.

Eosinophilia.

However, the complete triad is often absent.

Most important cause:

Drug-induced immune reaction.

Important drugs:

NSAIDs.

Penicillins and other antibiotics.

Sulfonamides.

Proton-pump inhibitors.

Other medications.

Infectious causes:

CMV.

Leptospirosis.

Mycobacterial infection.

Immune/systemic causes:

Sjögren syndrome.

Sarcoidosis.

SLE can cause tubulointerstitial disease, although lupus nephritis is primarily glomerular.

TINU syndrome.

Biopsy:

Interstitial oedema.

Inflammatory infiltrate.

Tubulitis.

± eosinophils.

Treatment:

Stop the offending drug.

Treat the underlying infection or systemic cause.

Supportive AKI management.

Consider corticosteroids in selected persistent or severe drug-induced cases.

47. Important Corrections to the Original Notes

The original presentation:

“Mild renal impairment”

is too restrictive.

AIN can cause:

MILD TO SEVERE ACUTE KIDNEY INJURY.

The classic triad:

FEVER + RASH + EOSINOPHILIA

is useful for exams but occurs in only a minority of patients.

Its absence does not exclude AIN.

The original list includes:

Goodpasture syndrome.

This should be corrected:

ANTI-GBM / GOODPASTURE DISEASE → RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS, NOT CLASSIC ACUTE INTERSTITIAL NEPHRITIS.

Important modern drug causes missing from the original list include:

PROTON-PUMP INHIBITORS.

The statement:

“Complete recovery in most people”

should be qualified.

Many recover substantially, but some are left with:

Persistent renal impairment or CKD.

Key Clinical Pattern

The classic pattern is:

NEW DRUG → AKI + STERILE PYURIA ± WBC CASTS ± FEVER/RASH/EOSINOPHILIA → THINK ACUTE INTERSTITIAL NEPHRITIS.

Remember:

AIN = INTERSTITIUM + TUBULES.

GLOMERULONEPHRITIS = GLOMERULI.

For treatment:

STOP THE OFFENDING DRUG FIRST.

And for prognosis:

EARLY DRUG WITHDRAWAL → BETTER RENAL RECOVERY.

PROLONGED INFLAMMATION → INTERSTITIAL FIBROSIS + TUBULAR ATROPHY → POSSIBLE CKD.

Medicine – Polycystic Kidney Disease

Polycystic kidney disease is an inherited disorder in which numerous fluid-filled cysts progressively develop within the kidneys. The most important adult form is autosomal dominant polycystic kidney disease, or ADPKD, which commonly causes hypertension, haematuria, recurrent urinary problems, progressive enlargement of the kidneys, and eventual chronic kidney disease.

1. Inheritance

The classic adult form is:

Autosomal dominant polycystic kidney disease.

Therefore, an affected person has a significant chance of transmitting the condition to each child.

The major genes are:

PKD1

and

PKD2.

PKD1 disease is generally more common and often more severe.

2. Development of Renal Cysts

The original note states that:

Multiple renal cysts develop in the teenage years.

This is broadly useful but somewhat simplified.

Cysts may begin developing much earlier, but they often become progressively more numerous and clinically apparent with age. Some affected individuals remain asymptomatic until adulthood.

3. Renal Enlargement

As cysts increase in number and size, the kidneys may become:

Markedly enlarged.

The cysts arise from different parts of the nephron and progressively distort normal renal architecture.

This can eventually reduce functioning renal tissue.

4. Abdominal or Flank Pain

A common presentation is:

Abdominal, loin, or flank pain.

Pain may result from:

Cyst enlargement.

Cyst haemorrhage.

Infection.

Renal calculi.

Capsular stretching.

Some patients develop a chronic dull ache, while others present with sudden severe pain.

5. Haematuria

Patients may develop:

Microscopic or visible haematuria.

This may occur due to:

Bleeding into a cyst.

Rupture of a cyst into the collecting system.

Renal calculi.

Urinary tract infection.

Episodes of visible haematuria can be dramatic but may resolve spontaneously.

6. Urinary Tract Infection

ADPKD increases the risk of:

Urinary tract infection.

Patients may develop:

Cystitis.

Pyelonephritis.

Infected renal cysts.

Infected cysts can be particularly difficult to treat because not all antibiotics penetrate cyst fluid equally well.

7. Hypertension

Hypertension is one of the earliest and most important manifestations of ADPKD.

It may develop before there is a major reduction in GFR.

The mechanism involves:

Compression of renal vessels by expanding cysts → local renal ischaemia → renin release → RAAS activation → hypertension.

8. Importance of Hypertension

Uncontrolled hypertension contributes to:

Faster progression of CKD.

Left ventricular hypertrophy.

Cardiovascular disease.

Therefore, early recognition and treatment of blood pressure is an important part of management.

9. Chronic Kidney Disease

Progressive cyst expansion destroys and compresses normal renal tissue.

Over time this can produce:

Chronic kidney disease, or CKD.

The older term:

Renal failure

is better separated into:

CKD

and, when advanced:

End-stage kidney disease, or ESKD.

10. Progression to ESKD

Not every patient progresses at the same rate.

Progression depends on factors such as:

Genetic subtype.

Kidney size.

Blood-pressure control.

Sex.

Family history.

Episodes of haematuria or infection.

Many patients with severe disease eventually require:

Dialysis or kidney transplantation.

11. Renal Calculi

An important additional renal association is:

Kidney stones.

Patients with ADPKD have an increased risk of renal calculi, which can contribute to:

Pain.

Haematuria.

Urinary obstruction.

Infection.

12. Liver Cysts

The most common extrarenal manifestation is:

Hepatic cysts.

These often increase in number with age.

They may be asymptomatic or, if extensive, produce:

Abdominal distension.

Discomfort.

Early satiety.

Liver function is often preserved despite extensive cystic disease.

13. Pancreatic Cysts

Patients may also develop:

Pancreatic cysts.

These are less common and often asymptomatic.

Their presence supports the concept that ADPKD is a:

Systemic cystic disorder

rather than a disease confined only to the kidneys.

14. Intracranial Berry Aneurysms

A major vascular association is:

Intracranial saccular, or berry, aneurysms.

These occur more frequently in ADPKD than in the general population.

15. Subarachnoid Haemorrhage

If a berry aneurysm ruptures, it may cause:

Subarachnoid haemorrhage.

The classic presentation is:

Sudden thunderclap headache.

This may be accompanied by:

Vomiting.

Neck stiffness.

Loss of consciousness.

Focal neurological signs.

16. Who Should Be Considered for Aneurysm Screening

Routine screening of every person with ADPKD is not always performed.

Screening may be considered particularly when there is:

A family history of intracranial aneurysm or subarachnoid haemorrhage.

Previous aneurysm.

High-risk occupation.

Planned major surgery or transplantation in selected settings.

The exact approach varies by clinical guideline and patient risk.

17. Mitral Valve Prolapse

ADPKD is associated with several cardiac valvular abnormalities, including:

Mitral valve prolapse.

Other valvular abnormalities may also occur.

This reflects the systemic connective-tissue and vascular manifestations of the disorder.

18. Other Cardiovascular Associations

Additional associations can include:

Aortic root dilatation.

Aortic regurgitation.

Other arterial aneurysms in selected patients.

However, intracranial aneurysm remains the most important classic examination association.

19. Malignant Change

The original notes list:

Malignant change.

This should be interpreted cautiously.

ADPKD is not usually taught as a major direct premalignant condition in the same way as some acquired cystic kidney diseases.

Patients with advanced CKD or long-term dialysis may have increased renal cancer risk, but:

“ADPKD → malignant transformation”

is too simplistic as a core association.

20. Important Distinction – Acquired Cystic Kidney Disease

Patients with long-standing ESKD, particularly those on dialysis, may develop:

Acquired cystic kidney disease.

This condition is associated with an increased risk of:

Renal cell carcinoma.

This is different from classical inherited ADPKD.

21. Physical Examination

Some patients may have:

Bilaterally enlarged palpable kidneys.

They may also have:

Hypertension.

Abdominal masses.

Signs of CKD in advanced disease.

Large polycystic kidneys can sometimes be felt on abdominal examination.

22. Diagnosis

Diagnosis may be based on:

Family history.

Ultrasound.

CT or MRI.

Genetic testing in selected cases.

Imaging demonstrates multiple bilateral renal cysts.

23. Ultrasound

Renal ultrasound is commonly used for screening and diagnosis.

It can demonstrate:

Multiple cysts in both kidneys.

Renal enlargement.

Liver cysts.

Age-dependent imaging criteria are often used because occasional simple cysts become more common with age.

24. CT and MRI

CT or MRI can provide more detailed assessment of:

Kidney size.

Cyst burden.

Complications such as haemorrhage or stones.

MRI can also be used to estimate:

Total kidney volume

in selected patients.

25. Genetic Testing

Genetic testing for:

PKD1

and

PKD2

may be helpful when:

Imaging is equivocal.

The family history is unclear.

Living-related kidney donation is being considered.

Early diagnosis has important implications.

26. Treatment Principles

There is no simple cure for ADPKD.

Management focuses on:

Blood-pressure control.

Preservation of kidney function.

Treatment of infection.

Treatment of stones.

Management of pain.

Monitoring for complications.

27. Blood-Pressure Treatment

Good blood-pressure control is particularly important.

ACE inhibitors or ARBs are commonly used because of their effects on:

RAAS activity

and

Renal protection.

The exact target depends on patient age, kidney function, and other clinical factors.

28. Tolvaptan

A major modern disease-modifying treatment is:

Tolvaptan.

This is a:

Vasopressin V2-receptor antagonist.

In selected patients at risk of rapidly progressive ADPKD, it can slow:

Kidney enlargement

and

Decline in renal function.

29. Monitoring with Tolvaptan

Tolvaptan can cause:

Polyuria.

Thirst.

It also carries a risk of:

Liver injury.

Therefore, patients require appropriate:

Liver-function monitoring.

30. Treatment of Infection

UTIs and pyelonephritis should be treated appropriately.

If an infected renal cyst is suspected, antibiotic choice may need to consider:

Cyst penetration.

Persistent fever or pain despite treatment may require further imaging.

31. Treatment of Pain

Pain management depends on the cause.

Possible causes include:

Cyst haemorrhage.

Stone disease.

Infection.

Large cysts.

Persistent focal symptoms may occasionally require specialist interventions.

32. Treatment of Kidney Stones

Stone disease is managed according to:

Stone size.

Location.

Presence of obstruction.

Presence of infection.

Treatment may include:

Fluids.

Analgesia.

Endoscopic treatment.

Lithotripsy or other urological procedures.

33. Renal Replacement Therapy

If patients progress to ESKD, treatment options include:

Haemodialysis.

Peritoneal dialysis in suitable patients.

Kidney transplantation.

Transplantation is an important long-term option for suitable patients.

34. Family Screening

Because ADPKD is inherited, first-degree relatives may require:

Counselling.

Blood-pressure measurement.

Urinalysis.

Imaging where appropriate.

The timing and method depend on age and clinical circumstances.

35. Autosomal Recessive Polycystic Kidney Disease

It is important not to confuse ADPKD with:

Autosomal recessive polycystic kidney disease, or ARPKD.

ARPKD usually presents in:

Infancy or childhood.

It is associated with:

Collecting duct dilatation.

Congenital hepatic fibrosis.

Portal hypertension.

This is a different disorder from adult ADPKD.

36. ADPKD – Note Form

Inheritance:

Autosomal dominant.

Genes:

PKD1.

PKD2.

Kidneys:

Multiple bilateral renal cysts.

Progressive renal enlargement.

Presentations:

Abdominal or flank pain.

Microscopic or visible haematuria.

UTI.

Hypertension.

Renal stones.

CKD.

Possible progression to ESKD.

37. Extrarenal Associations – Note Form

Liver:

Hepatic cysts.

Pancreas:

Pancreatic cysts.

Brain vessels:

Berry aneurysms.

Risk of subarachnoid haemorrhage if rupture occurs.

Heart:

Mitral valve prolapse.

Other valvular abnormalities may occur.

38. Important Corrections to the Original Notes

The statement:

“Multiple renal cysts develop in teenage years”

is too fixed.

Cysts may develop earlier, but clinical and imaging expression increases progressively with age.

The statement:

“Renal failure”

is better described as:

Progressive CKD with possible ESKD.

The statement:

“Malignant change”

should not be treated as a defining classical association of ADPKD.

An especially important distinction is:

Acquired cystic kidney disease in long-term ESKD/dialysis has a clearer association with renal cell carcinoma.

The original list also omits an important renal complication:

Renal calculi.

Modern treatment should also include consideration of:

Tolvaptan in selected patients with rapidly progressive disease.

Key Clinical Pattern

Remember:

ADPKD = AUTOSOMAL DOMINANT + BILATERAL RENAL CYSTS + HYPERTENSION + HAEMATURIA + PROGRESSIVE CKD.

Important extrarenal associations are:

LIVER CYSTS.

PANCREATIC CYSTS.

BERRY ANEURYSMS → SUBARACHNOID HAEMORRHAGE.

MITRAL VALVE PROLAPSE.

A very high-yield exam pattern is:

FAMILY HISTORY + HYPERTENSION + ENLARGED CYSTIC KIDNEYS + HAEMATURIA → THINK ADPKD.

And remember:

ADPKD + THUNDERCLAP HEADACHE → URGENTLY CONSIDER RUPTURED INTRACRANIAL ANEURYSM / SUBARACHNOID HAEMORRHAGE.

Medicine – Alport Syndrome

Alport syndrome is an inherited disorder caused by abnormalities in type IV collagen, an important structural component of basement membranes. It primarily affects the glomerular basement membrane of the kidney, but also the inner ear and eyes.

The classic clinical pattern is:

Persistent haematuria + progressive kidney disease + sensorineural hearing loss.

1. Genetic Basis

The most common form of Alport syndrome is:

X-linked Alport syndrome.

It is usually caused by pathogenic variants in the:

COL4A5 gene.

This gene encodes part of type IV collagen.

2. Inheritance Pattern

The original note states:

“X-linked dominant.”

This reflects older terminology.

Modern classification usually describes the common form simply as:

X-linked Alport syndrome.

There are also:

Autosomal recessive forms.

Autosomal dominant forms.

These usually involve other type IV collagen genes such as:

COL4A3 and COL4A4.

3. Type IV Collagen

Type IV collagen is a major structural component of:

Basement membranes.

It is particularly important in the:

Glomerular basement membrane.

Cochlea of the inner ear.

Lens and other ocular structures.

Therefore, a collagen defect can produce:

Renal + auditory + ocular abnormalities.

4. Glomerular Basement Membrane

The glomerular basement membrane, or:

GBM,

forms an important part of the renal filtration barrier.

In Alport syndrome, abnormal type IV collagen makes the GBM structurally abnormal and progressively unstable.

This leads initially to:

Haematuria

and later to:

Proteinuria and progressive renal impairment.

5. Early Renal Presentation

The earliest and most common renal feature is:

Persistent microscopic haematuria.

This may begin in:

Childhood.

Some patients may occasionally develop visible haematuria, particularly during:

Intercurrent infections.

6. Microscopic Haematuria

Microscopic haematuria may be present for years before renal function declines.

This is an important diagnostic clue, especially when combined with:

Family history of renal disease

or

Sensorineural deafness.

7. Proteinuria

As glomerular damage progresses, patients may develop:

Proteinuria.

This often indicates more advanced renal involvement than isolated haematuria.

Increasing proteinuria is associated with a greater risk of:

Progressive chronic kidney disease.

8. Chronic Kidney Disease

Progressive glomerular scarring eventually leads to:

Chronic kidney disease, or CKD.

The older term:

CRF – chronic renal failure

is better replaced with:

CKD.

Advanced disease may progress to:

End-stage kidney disease, or ESKD.

9. Sensorineural Hearing Loss

A major extrarenal feature is:

Sensorineural hearing loss.

This usually affects:

High-frequency hearing

and often develops during:

Late childhood or adolescence

in more severely affected patients.

10. Why Hearing Loss Occurs

Type IV collagen is important in basement membranes of the:

Cochlea.

Abnormal collagen disrupts normal cochlear function.

Therefore:

Alport syndrome → sensorineural deafness, not conductive deafness.

11. Hearing Loss and Kidney Disease

The combination:

Persistent microscopic haematuria + sensorineural hearing loss

should strongly suggest:

Alport syndrome.

This is particularly important in a male patient with a family history of:

Renal failure.

12. Ocular Abnormalities

The original notes do not mention the eye, but ocular abnormalities are an important part of Alport syndrome.

Classical findings include:

Anterior lenticonus.

Retinal flecks.

Other retinal abnormalities.

13. Anterior Lenticonus

Anterior lenticonus is highly characteristic.

The anterior surface of the lens becomes:

Cone-shaped or protruding.

It may cause:

Progressive visual impairment.

This finding strongly supports the diagnosis of Alport syndrome.

14. Retinal Changes

Patients may also develop:

Perimacular retinal flecks.

These are usually not the major cause of visual loss but can provide another diagnostic clue.

15. Renal Histology

Light microscopy may be relatively nonspecific, especially early in disease.

More characteristic abnormalities are seen on:

Electron microscopy.

16. Electron Microscopy

The glomerular basement membrane may show:

Irregular thickening and thinning.

Splitting and lamellation.

This produces the classic:

“Basket-weave” appearance.

17. Basket-Weave GBM

The basket-weave appearance results from:

Splitting and layering of the lamina densa of the GBM.

This is a classic pathological clue to:

Alport syndrome.

18. Early GBM Changes

In earlier disease, the GBM may show:

Diffuse thinning.

Later it becomes more irregular with:

Thickening, splitting, and lamellation.

Therefore, pathology may evolve as disease progresses.

19. Collagen Immunostaining

Modern diagnosis may also use:

Type IV collagen immunostaining

on kidney or skin tissue in selected cases.

However, increasingly, diagnosis is established by:

Genetic testing.

20. Genetic Testing

Genetic testing can identify pathogenic variants in:

COL4A3.

COL4A4.

COL4A5.

This can:

Confirm the diagnosis.

Clarify inheritance.

Help assess family members.

Guide genetic counselling.

21. Males with X-Linked Alport Syndrome

Males with pathogenic COL4A5 variants are generally more severely affected because they have:

Only one X chromosome.

Traditionally, affected males were said to:

All develop renal failure.

This is too absolute.

22. Renal Prognosis in Males

Many affected males do develop:

Progressive CKD and ESKD.

However, the:

Age of progression

and

Severity

vary considerably depending on the specific genetic variant.

Therefore, not every male reaches kidney failure at the same age, and some milder variants progress much more slowly.

23. Females with X-Linked Alport Syndrome

The original note states:

“Females: minor abnormalities only.”

This is also too simplistic.

Females are often less severely affected than males, but they are not simply unaffected carriers.

24. Renal Disease in Females

Females may develop:

Persistent microscopic haematuria.

Proteinuria.

Hypertension.

Progressive CKD.

A minority may eventually develop:

ESKD.

Therefore, women with X-linked Alport syndrome require proper long-term follow-up.

25. Why Females Are Variable

Females have two X chromosomes.

Because of:

X-chromosome inactivation,

the proportion of cells expressing the abnormal COL4A5 allele varies.

This contributes to major variation in disease severity between females.

26. Autosomal Recessive Alport Syndrome

Autosomal recessive disease is usually caused by pathogenic variants affecting both copies of:

COL4A3

or

COL4A4.

Both males and females can be:

Severely affected.

The clinical pattern can resemble severe X-linked disease.

27. Autosomal Dominant Alport Syndrome

Autosomal dominant forms usually involve one pathogenic variant in:

COL4A3

or

COL4A4.

These may cause:

Persistent haematuria

with variable:

Proteinuria and CKD progression.

Disease is often milder and later in onset than severe X-linked or autosomal recessive forms, although substantial CKD can still occur.

28. Family History

A useful family history may include:

Microscopic haematuria.

Progressive kidney failure.

Dialysis or transplantation at a young age.

Sensorineural hearing loss.

However, absence of an obvious family history does not exclude the disease because new pathogenic variants and unrecognised mild disease can occur.

29. Differential Diagnosis

Persistent familial haematuria can also occur with:

Thin basement membrane nephropathy / COL4A-related disease.

IgA nephropathy.

Other hereditary glomerular disorders.

Modern understanding increasingly recognises overlap among:

COL4A3, COL4A4, and COL4A5-related disorders.

30. Thin Basement Membrane Disease

Some patients with heterozygous COL4A3 or COL4A4 variants were historically labelled as having:

Thin basement membrane nephropathy.

These patients may have isolated haematuria, but some can develop:

Proteinuria and CKD.

Thus the distinction from the broader Alport spectrum is less absolute than older teaching suggested.

31. Treatment Principles

There is no simple treatment that replaces defective collagen.

Management therefore aims to:

Slow renal progression.

Reduce proteinuria.

Control blood pressure.

Monitor hearing and vision.

Provide genetic counselling.

32. ACE Inhibitors

One of the most important renal treatments is:

ACE inhibitor therapy

especially once albuminuria or proteinuria develops.

ACE inhibitors reduce:

Intraglomerular pressure.

Proteinuria.

They can slow progression of kidney disease.

33. ARBs

If an ACE inhibitor is not tolerated, an:

Angiotensin II receptor blocker, or ARB

may be considered.

As in other proteinuric kidney diseases:

ACE inhibitor and ARB should not routinely be combined.

34. Blood-Pressure Control

Good blood-pressure control is important because hypertension accelerates:

Glomerular damage

and

Loss of renal function.

Patients require regular monitoring of:

Blood pressure.

Urinary albumin/protein.

Creatinine and eGFR.

35. Hearing Management

Patients should undergo:

Audiological assessment

when clinically appropriate.

Progressive sensorineural hearing loss may require:

Hearing aids

or other specialist hearing support.

36. Eye Assessment

Ophthalmological assessment may identify:

Anterior lenticonus.

Retinal abnormalities.

Treatment depends on the specific ocular complication.

37. Kidney Transplantation

Patients who progress to ESKD may undergo:

Kidney transplantation.

Transplant outcomes are generally good.

The transplanted kidney contains normal type IV collagen and is not affected by the inherited GBM defect.

38. Anti-GBM Disease after Transplantation

A rare complication after transplantation is the development of:

Anti-glomerular basement membrane antibodies.

This can cause:

Anti-GBM nephritis in the transplanted kidney.

It is uncommon but classically associated with some severely affected Alport patients.

39. Genetic Counselling

Because Alport syndrome is inherited, patients and families may benefit from:

Genetic counselling.

This can help clarify:

Inheritance risk.

Testing of relatives.

Reproductive implications.

Need for renal surveillance in family members.

40. Alport Syndrome – Note Form

Cause:

Inherited type IV collagen disorder.

Genes:

COL4A5 most common X-linked form.

COL4A3 and COL4A4 in autosomal forms.

Main renal feature:

Persistent microscopic haematuria.

Progression:

Haematuria → proteinuria → CKD → possible ESKD.

Hearing:

Sensorineural deafness.

Eyes:

Anterior lenticonus.

Retinal flecks.

Biopsy / electron microscopy:

GBM thinning early.

Later irregular thickening, splitting and lamellation.

Classic:

Basket-weave appearance.

Males with X-linked disease:

Usually more severely affected.

Many progress to ESKD, but age and severity vary.

Females with X-linked disease:

Often milder, but may develop haematuria, proteinuria, hypertension, CKD and occasionally ESKD.

They are not always just mildly affected carriers.

Treatment:

ACE inhibitor or ARB where indicated.

Good blood-pressure control.

Renal monitoring.

Hearing and eye follow-up.

Kidney transplantation for ESKD.

Genetic counselling.

41. Important Corrections to the Original Notes

The statement:

“Alport syndrome is X-linked dominant”

is incomplete.

The most common form is:

X-linked Alport syndrome due to COL4A5,

but autosomal recessive and autosomal dominant forms also occur.

The statement:

“All males develop renal failure”

is too absolute.

A better description is:

Affected males are generally at much higher risk of progressive CKD and ESKD, but severity and age of onset vary with genotype.

The statement:

“Females have minor abnormalities only”

is incorrect.

Females may develop:

Proteinuria, hypertension, progressive CKD, and occasionally ESKD.

Therefore, affected women require long-term monitoring.

The older term:

CRF

is better replaced with:

CKD – chronic kidney disease.

Key Clinical Pattern

Remember:

ALPORT = KIDNEY + EAR + EYE.

The classic combination is:

PERSISTENT MICROSCOPIC HAEMATURIA + SENSORINEURAL DEAFNESS + FAMILY HISTORY OF RENAL FAILURE.

For pathology:

TYPE IV COLLAGEN DEFECT → ABNORMAL GBM → BASKET-WEAVE APPEARANCE ON ELECTRON MICROSCOPY.

For genetics:

COL4A5 → MOST COMMON X-LINKED FORM.

And the important modern correction is:

MALES ARE USUALLY MORE SEVERELY AFFECTED, BUT FEMALES CAN ALSO DEVELOP SIGNIFICANT CKD.

Medicine – Renal Calculi

Renal calculi, or kidney stones, are crystalline concretions that form within the urinary tract when substances in the urine become supersaturated and precipitate. They may remain within the kidney, pass into the ureter, or cause obstruction, infection, haematuria, and severe colicky pain.

The overall prevalence varies by population and has increased in many countries over time, so the older figure of 3% in the UK should be regarded as historical rather than a fixed modern prevalence estimate.

1. Types of Renal Calculi

The major stone types are:

Calcium-containing stones.

Uric acid stones.

Struvite stones.

Cystine stones.

Calcium-containing stones are the most common.

2. Calcium Stones

Most renal stones contain calcium, usually as:

Calcium oxalate

and less commonly:

Calcium phosphate.

They account for the majority of urinary calculi.

3. Hypercalciuria

Hypercalciuria is one of the most important metabolic risk factors for calcium stones.

It may occur even when the:

Serum calcium is normal.

This is called:

Idiopathic hypercalciuria

and is a common cause of recurrent calcium stone formation.

4. Hypercalcaemia

Conditions causing hypercalcaemia can increase filtered urinary calcium and predispose to stones.

Important examples include:

Primary hyperparathyroidism.

Malignancy-associated hypercalcaemia.

Excess vitamin D states.

Sarcoidosis in selected patients.

A classic exam association is:

Primary hyperparathyroidism → hypercalcaemia + hypercalciuria → calcium stones.

5. Renal Tubular Acidosis

Distal, or type 1, renal tubular acidosis is strongly associated with:

Calcium phosphate stones.

It causes:

Inappropriately alkaline urine.

Hypocitraturia.

Nephrocalcinosis.

These changes favour calcium phosphate precipitation.

6. Uric Aciduria

Increased urinary uric acid can contribute to stone formation.

This may produce:

Uric acid stones

or may promote calcium oxalate crystallisation.

Conditions associated with high uric acid include:

Gout.

High cell turnover.

Tumour lysis.

Myeloproliferative disorders.

High purine intake.

7. Uric Acid Stones

Uric acid stones are favoured particularly by:

Persistently acidic urine.

They are associated with:

Gout.

Metabolic syndrome.

Diabetes.

Obesity.

High purine intake.

High cell turnover.

A key feature is that uric acid stones are usually:

Radiolucent on plain X-ray

although they are visible on CT.

8. Hyperoxaluria

Hyperoxaluria increases the risk of:

Calcium oxalate stones.

This may result from:

Excess intestinal oxalate absorption.

Enteric disease.

Malabsorption.

Short bowel disease.

Certain bariatric procedures.

Rare inherited primary hyperoxaluria.

9. Enteric Hyperoxaluria

In fat malabsorption, free fatty acids bind intestinal calcium.

This leaves more oxalate unbound and available for absorption.

Therefore:

Fat malabsorption → less calcium available to bind oxalate → increased oxalate absorption → hyperoxaluria → calcium oxalate stones.

10. Low Urinary Citrate

An important additional risk factor is:

Hypocitraturia.

Citrate normally binds calcium and reduces crystal formation.

Low urinary citrate therefore predisposes to:

Calcium stone formation.

It may occur in:

Distal renal tubular acidosis.

Chronic diarrhoea.

Metabolic acidosis.

11. Dehydration

Low urine volume is one of the most important general risk factors for all major stone types.

Dehydration causes urine to become more concentrated.

Therefore:

Low fluid intake or high fluid loss → concentrated urine → increased supersaturation → stone formation.

12. Structural Predisposing Factors

Structural abnormalities of the urinary tract may promote:

Urinary stasis.

Recurrent infection.

Crystal retention.

These factors increase the likelihood of stone formation.

13. Polycystic Kidney Disease

Polycystic kidney disease may be associated with renal stones.

Distorted renal anatomy and altered urinary composition can contribute.

Patients may also develop:

Haematuria.

UTI.

Flank pain.

which can overlap with stone symptoms.

14. Reflux Nephropathy

Reflux nephropathy may predispose indirectly through:

Urinary tract distortion.

Scarring.

Recurrent infection.

However, it is not one of the strongest primary metabolic causes of stone disease.

15. Nephrocalcinosis

Nephrocalcinosis means diffuse calcium deposition within renal tissue.

It is not itself the same as a urinary stone, but conditions causing nephrocalcinosis often also predispose to calculi.

Examples include:

Hyperparathyroidism.

Distal renal tubular acidosis.

Medullary sponge kidney.

16. Medullary Sponge Kidney

Medullary sponge kidney is a congenital disorder involving cystic dilatation of collecting ducts.

It is associated with:

Nephrocalcinosis.

Calcium stones.

Haematuria.

Recurrent urinary tract infection.

17. Struvite Stones

Struvite stones are composed mainly of:

Magnesium ammonium phosphate.

They form in alkaline urine due to infection with:

Urease-producing organisms.

The classic organism is:

Proteus.

Other urease-producing organisms may also contribute.

18. Mechanism of Struvite Stone Formation

Urease breaks down urea into ammonia.

This raises urinary pH.

The sequence is:

Urease-producing bacteria → alkaline urine → magnesium ammonium phosphate precipitation → struvite stone.

19. Staghorn Calculi

Large struvite stones can grow to fill the renal pelvis and calyces.

These are called:

Staghorn calculi.

They are strongly associated with:

Chronic urinary infection.

Recurrent pyelonephritis.

Renal damage.

20. Cystine Stones

Cystine stones occur in:

Cystinuria.

Cystinuria is an inherited defect in renal tubular reabsorption of certain dibasic amino acids.

A useful mnemonic is:

COLA

for:

Cystine.

Ornithine.

Lysine.

Arginine.

21. Cystine Crystal Appearance

Cystine crystals classically appear:

Hexagonal

on urine microscopy.

This is a very high-yield examination finding.

22. Clinical Presentation

Renal calculi may present in several ways.

Possible presentations include:

No symptoms.

Renal colic.

Haematuria.

Urinary infection.

Obstruction.

Hydronephrosis.

Pyelonephritis.

23. Asymptomatic Stones

Some renal stones are discovered:

Incidentally on imaging.

They may remain asymptomatic if they do not obstruct urine flow or irritate the urothelium.

24. Renal Colic

The classic symptom of a ureteric stone is:

Renal colic.

This is severe intermittent pain caused by:

Ureteric obstruction and muscular spasm.

25. Character of Renal Colic

Renal colic typically begins in the:

Flank or loin

and may radiate toward the:

Groin.

Lower abdomen.

Testicle in men.

Labia in women.

The pain often comes in waves and may be extremely severe.

26. Restlessness

Unlike patients with peritonitis, who often lie still, patients with renal colic are typically:

Restless and unable to find a comfortable position.

This is a useful clinical distinction.

27. Haematuria

Stones can traumatise the urothelium and cause:

Microscopic haematuria

or

Visible haematuria.

However, absence of haematuria does not completely exclude a stone.

28. Proteinuria

The original list includes:

Proteinuria.

Mild proteinuria can occur, but it is not one of the most characteristic features of uncomplicated renal calculi.

Prominent proteinuria should prompt consideration of:

Additional renal pathology.

29. Cystitis and Lower UTI

Stones can predispose to:

Recurrent urinary tract infection

through urinary stasis and persistent bacterial colonisation.

Lower infection may cause:

Dysuria.

Frequency.

Urgency.

Suprapubic discomfort.

30. Pyelonephritis

Stones can predispose to:

Upper urinary tract infection.

A patient may develop:

Fever.

Flank pain.

Systemic illness.

Pyuria.

The combination of infection and obstruction is particularly dangerous.

31. Infected Obstructed Kidney

An:

Obstructed infected urinary system

is a urological emergency.

It can rapidly lead to:

Sepsis.

Renal damage.

Pyonephrosis.

32. Pyonephrosis

Pyonephrosis is infection of an obstructed renal collecting system with accumulation of pus.

This requires:

Urgent drainage

in addition to:

Antibiotic therapy.

33. Urinary Obstruction

A stone lodged in the ureter can obstruct urine flow.

This may produce:

Hydroureter.

Hydronephrosis.

Reduced renal function.

If obstruction is bilateral or occurs in a solitary functioning kidney, it may cause:

Acute kidney injury.

34. Common Sites of Ureteric Obstruction

Stones tend to lodge at naturally narrower points.

Traditional teaching includes:

Pelvi-ureteric junction.

Crossing of the iliac vessels.

Vesicoureteric junction.

The vesicoureteric junction is a particularly common site.

35. Investigation – Urinalysis

Urinalysis may show:

Blood.

Leukocytes.

Nitrites if infection is present.

Crystals.

Urine pH can also give clues to stone type.

36. Urine pH

Acidic urine favours:

Uric acid stones.

Cystine stones.

Alkaline urine favours:

Calcium phosphate stones.

Struvite stones.

37. Imaging

For suspected acute renal colic, the most useful imaging test in many adults is:

Non-contrast CT of the kidneys, ureters and bladder.

This is often called:

CT KUB.

It is highly sensitive for most urinary calculi.

38. Ultrasound

Renal ultrasound can identify:

Hydronephrosis.

Some renal stones.

It avoids radiation and is particularly useful in:

Pregnancy.

Children.

Certain follow-up situations.

39. Plain Abdominal X-Ray

Some stones are radiopaque and may be visible on:

Plain KUB X-ray.

Calcium stones are usually radiopaque.

Uric acid stones are usually:

Radiolucent.

CT, however, detects both.

40. Treatment – Acute Renal Colic

Initial treatment focuses on:

Pain relief.

Assessment for obstruction.

Assessment for infection.

Assessment of renal function.

Hydration appropriate to clinical status.

NSAIDs are often effective analgesics if not contraindicated.

41. Increased Fluid Intake

Long-term prevention often includes:

Increased fluid intake.

The aim is to produce a high urine volume and reduce urinary supersaturation.

A general preventive principle is:

More dilute urine → lower risk of crystal precipitation.

42. Important Correction – Do Not Routinely Restrict Calcium

The original note states:

“Reduced Ca²⁺ intake.”

This is generally not recommended for most patients with calcium stones.

A normal dietary calcium intake is usually preferred.

Too little dietary calcium may actually increase intestinal oxalate absorption and increase calcium oxalate stone risk.

43. Dietary Calcium

The better principle is:

Maintain normal dietary calcium intake.

At the same time, reduce excessive:

Sodium intake.

High sodium intake increases urinary calcium excretion.

Therefore:

High salt → increased calciuria → increased calcium stone risk.

44. Oxalate Reduction

In selected patients with hyperoxaluria or calcium oxalate stones, reducing excessive high-oxalate foods may help.

Examples include:

Spinach.

Rhubarb.

Nuts.

Certain teas.

However, dietary changes should be targeted rather than excessively restrictive.

45. Sodium Restriction

Reducing:

Excess dietary sodium

can lower urinary calcium excretion.

This is particularly useful in patients with:

Hypercalciuria.

46. Animal Protein

Excessive animal protein intake may increase stone risk by:

Increasing uric acid excretion.

Lowering urinary citrate.

Increasing acid load.

Moderation may therefore help recurrent stone formers.

47. Thiazide Diuretics

Thiazide diuretics reduce urinary calcium excretion.

Therefore, they may be useful in selected patients with:

Recurrent calcium stones + persistent hypercalciuria.

Their preventive benefit is greatest when combined with appropriate dietary measures, especially lower sodium intake.

48. Potassium Citrate

An important modern preventive treatment is:

Potassium citrate.

It increases urinary citrate and can also alkalinise urine.

It is useful in selected patients with:

Hypocitraturia.

Recurrent calcium stones.

Uric acid stones.

Cystine stones in some cases.

49. Uric Acid Stones – Treatment

Uric acid stones may often be treated or prevented by:

Urinary alkalinisation.

This is commonly achieved with:

Potassium citrate.

The aim is to raise urinary pH so that uric acid becomes more soluble.

50. Allopurinol

Allopurinol may be useful in selected patients with:

Hyperuricosuria.

Recurrent uric acid stones.

Certain recurrent calcium oxalate stones with high urinary uric acid.

It is not required for every patient with a uric acid stone.

51. Struvite Stones – Treatment

Struvite stones require treatment of:

The underlying urinary infection

and often:

Complete stone removal.

Residual infected stone material can lead to recurrence.

52. Cystine Stones – Treatment

Management may include:

Very high fluid intake.

Urinary alkalinisation.

In refractory cases, additional drugs that bind cystine may be considered.

These patients often require specialist metabolic follow-up.

53. Stone Removal

Intervention is considered when stones:

Do not pass spontaneously.

Cause persistent obstruction.

Cause uncontrolled pain.

Cause infection.

Threaten renal function.

Are large or anatomically unsuitable for conservative management.

54. Extracorporeal Shock-Wave Lithotripsy

Extracorporeal shock-wave lithotripsy, or ESWL, uses external shock waves to fragment stones.

The fragments can then pass through the urinary tract.

Suitability depends on:

Stone size.

Stone location.

Stone composition.

Patient anatomy.

55. Ureteroscopy

Ureteroscopy allows direct endoscopic access to ureteric stones.

The stone can be:

Extracted

or

Fragmented with laser lithotripsy.

56. Percutaneous Nephrolithotomy

Large renal stones, especially:

Staghorn calculi,

may require:

Percutaneous nephrolithotomy, or PCNL.

This involves accessing the kidney through the skin and removing or fragmenting the stone.

57. Emergency Decompression

If there is:

Infection + urinary obstruction,

the priority is not definitive stone fragmentation.

The priority is:

Urgent drainage of the infected obstructed system.

This may be achieved using:

Ureteric stent

or

Percutaneous nephrostomy.

Definitive stone treatment is usually performed after infection has been controlled.

58. Metabolic Evaluation

Patients with recurrent stones may need metabolic investigation.

This can include:

Serum calcium.

Renal function.

Uric acid.

Bicarbonate.

Parathyroid hormone if hypercalcaemia.

Urinary stone analysis.

24-hour urine studies in selected recurrent/high-risk patients.

59. Stone Analysis

Whenever possible, a passed or removed stone should be sent for:

Stone composition analysis.

This can identify:

Calcium oxalate.

Calcium phosphate.

Uric acid.

Struvite.

Cystine.

The result helps guide prevention.

60. Renal Calculi – Note Form

Most common type:

Calcium-containing stones.

Especially calcium oxalate.

Metabolic risk factors:

Hypercalciuria.

Hypercalcaemia, especially primary hyperparathyroidism.

Distal renal tubular acidosis.

Hyperuricosuria.

Hyperoxaluria.

Hypocitraturia.

Structural associations:

Polycystic kidney disease.

Medullary sponge kidney.

Nephrocalcinosis-associated disorders.

Urinary tract abnormalities causing stasis.

General risk factor:

Dehydration / low urine volume.

61. Clinical Features – Note Form

Asymptomatic:

Some stones are incidentally detected.

Renal colic:

Severe loin-to-groin colicky pain.

Patient often restless.

Haematuria:

Microscopic or visible.

UTI:

Stones may predispose to cystitis or pyelonephritis.

Pyonephrosis:

Pus in an obstructed collecting system.

Urological emergency.

Obstruction:

May cause hydronephrosis and renal impairment.

62. Treatment – Note Form

Fluids:

Increase fluid intake for prevention.

Diet:

Maintain normal dietary calcium.

Reduce excessive sodium.

Reduce excessive oxalate in selected patients.

Moderate excessive animal protein.

Underlying cause:

Treat hyperparathyroidism, infection, RTA, metabolic abnormalities, or structural disease where possible.

Hypercalciuria:

Thiazide may be used in selected recurrent calcium stone formers.

Hypocitraturia / uric acid stones:

Potassium citrate may be useful.

Stone removal:

ESWL.

Ureteroscopy.

PCNL.

Choice depends on stone size and location.

Infected obstruction:

Urgent decompression with ureteric stent or nephrostomy.

63. Important Corrections to the Original Notes

The statement:

“Reduce calcium intake”

should generally be corrected.

For most calcium stone formers:

NORMAL DIETARY CALCIUM IS PREFERRED.

Excessive calcium restriction can increase oxalate absorption and may worsen calcium oxalate stone risk.

The original list does not include two very important stone types:

Struvite stones

and

Cystine stones.

Another important metabolic risk factor is:

Hypocitraturia.

The original symptom:

Proteinuria

is possible but not a classic dominant feature of uncomplicated nephrolithiasis.

Marked proteinuria should suggest additional renal disease.

Key Clinical Pattern

Think:

CALCIUM OXALATE = MOST COMMON RENAL STONE.

Important associations:

HYPERCALCIURIA → CALCIUM STONES.

PRIMARY HYPERPARATHYROIDISM → HYPERCALCAEMIA/HYPERCALCIURIA → CALCIUM STONES.

DISTAL RTA → ALKALINE URINE + CALCIUM PHOSPHATE STONES.

PROTEUS → UREASE → ALKALINE URINE → STRUVITE / STAGHORN STONE.

GOUT / ACIDIC URINE → URIC ACID STONES.

CYSTINURIA → HEXAGONAL CYSTINE CRYSTALS.

For acute presentation:

SEVERE LOIN-TO-GROIN COLIC + HAEMATURIA → THINK URETERIC STONE.

And the major emergency is:

STONE + FEVER/SEPSIS + OBSTRUCTION = INFECTED OBSTRUCTED KIDNEY → URGENT DRAINAGE.

Medicine – Amyloidosis

Amyloidosis is a group of disorders in which abnormal misfolded proteins aggregate into insoluble fibrils and are deposited in extracellular tissues. These deposits can progressively disrupt the structure and function of affected organs.

The kidney is one of the most important organs involved, but amyloid may also affect the heart, liver, spleen, gastrointestinal tract, peripheral nerves, and soft tissues.

1. What Amyloid Is

Amyloid is not one single protein.

Instead, the term describes a characteristic fibrillar protein structure that can be formed by several different precursor proteins.

The fibrils share a common appearance and staining pattern despite arising from different proteins.

2. General Mechanism

The basic sequence is:

Abnormal precursor protein → protein misfolding → fibril formation → extracellular deposition → organ dysfunction.

The exact precursor protein determines the type of amyloidosis and therefore the underlying disease and treatment.

3. Major Classification of Amyloidosis

Important systemic forms include:

AL amyloidosis.

AA amyloidosis.

ATTR amyloidosis.

Dialysis-related amyloidosis.

These categories are more useful than the older terms “primary,” “secondary,” and “senile” alone.

4. AL Amyloidosis

AL amyloidosis is caused by deposition of:

Immunoglobulin light chains.

The abnormal light chains are usually produced by a clonal population of:

Plasma cells.

This is why AL amyloidosis is strongly associated with plasma-cell disorders.

5. Primary Amyloidosis

The older term:

Primary amyloidosis

usually refers to:

AL amyloidosis.

It may occur with a relatively small plasma-cell clone or alongside a more obvious plasma-cell malignancy.

6. Multiple Myeloma and AL Amyloidosis

Multiple myeloma is associated with:

AL amyloidosis.

Therefore, myeloma should not be listed as a cause of secondary AA amyloidosis.

This is an important correction to the original notes.

The association is:

Myeloma → monoclonal immunoglobulin light chains → AL amyloid.

7. AA Amyloidosis

AA amyloidosis is the classic form of:

Secondary amyloidosis.

It occurs as a complication of chronic inflammatory or infectious disease.

The precursor protein is:

Serum amyloid A protein.

Serum amyloid A is an:

Acute-phase reactant

produced mainly by the liver during persistent inflammation.

8. Important Correction to the Original Classification

The original note states:

“Secondary amyloid – AA or AL.”

This is incorrect.

The classic pattern is:

Primary/plasma-cell-associated amyloidosis → AL.

Secondary inflammatory amyloidosis → AA.

9. Chronic Inflammation and AA Amyloidosis

Persistent inflammation causes prolonged elevation of:

Serum amyloid A.

If this continues for years, abnormal fragments can accumulate as amyloid fibrils in tissues.

The kidneys are especially vulnerable.

10. Rheumatoid Arthritis

Rheumatoid arthritis is a classical cause of AA amyloidosis.

Historically, chronic uncontrolled RA was an important cause.

With modern anti-inflammatory and biologic therapy, AA amyloidosis has become less frequent in many populations.

11. Seronegative Inflammatory Arthritis

Chronic inflammatory arthropathies can also produce AA amyloidosis.

Examples include selected cases of:

Ankylosing spondylitis.

Psoriatic arthritis.

Other chronic inflammatory arthritides.

The risk is related mainly to persistent inflammatory activity.

12. Systemic Sclerosis

Older lists sometimes include:

Scleroderma/systemic sclerosis

among causes of secondary amyloidosis.

However, it is not one of the strongest classical modern associations.

More important causes to remember are:

Chronic inflammatory arthritis.

Inflammatory bowel disease.

Chronic infections.

Autoinflammatory disorders.

13. Inflammatory Bowel Disease

Both:

Crohn disease

and

Ulcerative colitis

may be associated with chronic inflammation and AA amyloidosis.

The risk is greater when inflammatory activity is:

Severe and prolonged.

14. Tuberculosis

Chronic:

Tuberculosis

is a classical infectious cause of AA amyloidosis.

Before effective antimicrobial therapy, chronic infections such as TB were major causes of secondary amyloid deposition.

15. Chronic Osteomyelitis

Long-standing:

Osteomyelitis

can maintain persistent systemic inflammation.

This can produce sustained serum amyloid A elevation and eventually:

AA amyloidosis.

16. Bronchiectasis

Chronic suppurative lung disease such as:

Bronchiectasis

is another classical cause.

Repeated infection and inflammation may lead to:

AA amyloid deposition.

17. Other Causes of AA Amyloidosis

Important additional causes include:

Familial Mediterranean fever.

Other autoinflammatory syndromes.

Chronic inflammatory diseases.

Long-standing chronic infection.

Familial Mediterranean fever is a particularly high-yield modern association.

18. ATTR Amyloidosis

ATTR amyloidosis is caused by deposition of:

Transthyretin.

Transthyretin was historically called:

Prealbumin.

It is mainly produced in the liver.

19. Wild-Type ATTR Amyloidosis

The older term:

Senile systemic amyloidosis

has largely been replaced by:

Wild-type transthyretin amyloidosis, or wild-type ATTR.

It mainly affects older adults, particularly men.

The heart is commonly involved.

20. Wild-Type ATTR and the Heart

Wild-type ATTR can cause:

Restrictive/infiltrative cardiomyopathy.

Typical features may include:

Heart failure with preserved ejection fraction.

Increased ventricular wall thickness.

Conduction abnormalities.

Atrial arrhythmias.

It may also be associated with:

Carpal tunnel syndrome.

21. Hereditary ATTR Amyloidosis

Mutations in the transthyretin gene can produce:

Hereditary ATTR amyloidosis.

Depending on the mutation, patients may develop:

Peripheral neuropathy.

Autonomic neuropathy.

Cardiomyopathy.

Mixed neurological and cardiac disease.